[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1105
1. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res; 2007 Feb 1;13(3):902-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We examined the infiltration of FOXP3+ Tregs and CD8+ T cells in the tumor stroma and nontumorous liver parenchyma using 323 hepatic nodules including precursor lesions, early hepatocellular carcinoma (HCC), and advanced HCC, along with 39 intrahepatic cholangiocarcinomas and 59 metastatic liver adenocarcinomas.
  • RESULTS: The prevalence of Tregs was significantly higher in HCC than in the nontumorous liver (P<0.001).
  • Regardless of the presence of hepatitis virus infection or histopathologic evidence of hepatitis, the prevalence of Tregs was significantly increased in nontumorous liver bearing primary hepatic tumors.
  • It has been suggested that primary hepatic cancers develop in liver that is immunosuppressed by a marked infiltration of Tregs.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Forkhead Transcription Factors / biosynthesis. Liver Neoplasms / metabolism. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD8-Positive T-Lymphocytes / metabolism. Cholangiocarcinoma / metabolism. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289884.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


2. Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Kim YI: Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Surg; 2008 Jan;393(1):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis.
  • BACKGROUND/AIM: This study was conducted to devise a prognostic model for patients undergoing simultaneous liver and colorectal resection.
  • MATERIALS AND METHODS: A retrospective analysis was performed on 138 colorectal patients who underwent simultaneous liver and colorectal resection between September 1994 and September 2005.
  • The primary endpoint of the study was overall survival.
  • Three patients with positive liver resection margin were excluded from the analysis.
  • RESULTS: At multivariate level, poor prognostic factors were liver resection margin < or =5 mm (P = 0.047; relative risk, 1.684; 95% CI = 1.010-2.809), CEA greater than 5 ng/ml (P = <0.001; relative risk, 2.507; 95% CI = 1.499-4.194), number of liver metastasis > 1 (P = <0.042; relative risk, 1.687; 95% CI = 1.020-2.789), and lymph node > or = 4 (P = <0.012; relative risk, 1.968; 95% CI = 1.158-3.347).
  • CONCLUSIONS: A simple risk factor stratification system was proposed to evaluate the chances of cure of patients after simultaneous resection of liver metastases and primary colorectal carcinoma.
  • The risk stratification may help to predict patient survival after simultaneous liver and colorectal resection.
  • [MeSH-major] Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Colon / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Liver / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Rectum / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1401-9 [16472935.001]
  • [Cites] Langenbecks Arch Surg. 1999 Aug;384(4):313-27 [10473851.001]
  • [Cites] Cancer Res Treat. 2002 Apr;34(2):77-83 [26680846.001]
  • [Cites] Surgery. 1994 Oct;116(4):703-10; discussion 710-1 [7940169.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1240-3 [14515293.001]
  • [Cites] Surgery. 2004 Sep;136(3):650-9 [15349115.001]
  • [Cites] Eur J Surg Oncol. 1990 Aug;16(4):360-5 [2379594.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1105-12 [2045852.001]
  • [Cites] Ann Surg. 1992 Oct;216(4):493-504; discussion 504-5 [1417198.001]
  • [Cites] Am Surg. 1997 Jul;63(7):605-10 [9202534.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):529-34 [16622122.001]
  • [Cites] Hong Kong Med J. 2002 Oct;8(5):329-33 [12376709.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1059-69 [14597445.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Ann Surg. 1988 Dec;208(6):679-87 [3196088.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1081-4 [9278645.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):591-602 [16056258.001]
  • [Cites] World J Surg. 1998 Mar;22(3):268-76; discussion 276-7 [9494419.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):7-11 [10770561.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):254-60 [7840389.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Arch Surg. 2006 May;141(5):460-6; discussion 466-7 [16702517.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • (PMID = 17909846.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol; 2007 Jul 1;222(1):42-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues.
  • Frequently, primary hepatocytes are used as an in vitro model for the liver in vivo.
  • In this study, we characterized the differentiation character of primary human hepatocytes cultured using a highly defined, serum-free two-dimensional sandwich system, one that configures hepatocytes with collagen I as the substratum together with a dilute extracellular matrix (Matrigeltrade mark) overlay combined with a defined serum-free medium containing nanomolar levels of dexamethasone.
  • Whole genome expression profiling enabled direct comparison of liver tissues to hepatocytes and to the hepatoma-derived cell lines, HepG2 and Huh7.
  • The robustness of the primary hepatocyte cultures was reflected by the extent of unchanged expression character when compared directly to liver, with more than 77% of the probe sets unchanged in each of the over-represented categories, representing such genes as C/EBPalpha, HNF4alpha, CYP2D6, and ABCB1.
  • In contrast, HepG2 and Huh7 cells were unchanged from the liver tissues for fewer than 48% and 55% of these probe sets, respectively.
  • Further, hierarchical clustering of the hepatocytes, but not the cell lines, shifted from donor-specific to treatment-specific when the probe sets were filtered to focus on phenobarbital-inducible genes, indicative of the highly differentiated nature of the hepatocytes when cultured in a highly defined two-dimensional sandwich system.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Phenobarbital .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W645-50 [16912992.001]
  • [Cites] Toxicol In Vitro. 2002 Feb;16(1):89-99 [11812644.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1293-303 [11322933.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):219-31 [12011481.001]
  • [Cites] Xenobiotica. 2002 Jun;32(6):505-20 [12160483.001]
  • [Cites] Science. 2002 Oct 11;298(5592):422-4 [12376703.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Mol Endocrinol. 2003 Jul;17(7):1268-82 [12663745.001]
  • [Cites] Drug Metab Dispos. 2003 Aug;31(8):1035-42 [12867492.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):208-22 [12832660.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] Exp Cell Res. 2004 Jan 15;292(2):252-64 [14697333.001]
  • [Cites] Mol Pharmacol. 2004 Mar;65(3):550-7 [14978233.001]
  • [Cites] Genomics. 2004 Apr;83(4):541-9 [15028276.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22250-7 [15004017.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1294-302 [15290872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2161-5 [3353374.001]
  • [Cites] Arch Biochem Biophys. 1993 Feb 15;301(1):103-13 [8442654.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):373-85 [8745335.001]
  • [Cites] Methods Enzymol. 1996;272:388-401 [8791798.001]
  • [Cites] Toxicol Pathol. 1996 Jan-Feb;24(1):48-57 [8839280.001]
  • [Cites] Arch Biochem Biophys. 1997 Jan 15;337(2):275-83 [9016823.001]
  • [Cites] Biochem Pharmacol. 1997 Oct 1;54(7):761-72 [9353130.001]
  • [Cites] Drug Metab Dispos. 1999 Jun;27(6):637-44 [10348791.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):887-94 [10421615.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):909-15 [10421618.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49517-22 [15358766.001]
  • [Cites] Drug Metab Dispos. 2005 Mar;33(3):388-94 [15608134.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):927-34 [15772367.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Reprod Toxicol. 2005 Sep-Oct;20(3):433-40 [15964738.001]
  • [Cites] Toxicology. 2006 Feb 1;218(2-3):205-15 [16337326.001]
  • [Cites] BMC Bioinformatics. 2006;7:49 [16448562.001]
  • [Cites] Mol Pharmacol. 2002 Jan;61(1):1-6 [11752199.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • (PMID = 17512962.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES011387-02; United States / NIEHS NIH HHS / ES / U19 ES011387-05; United States / NIGMS NIH HHS / GM / R01 GM066411-03; United States / NIGMS NIH HHS / GM / R01 GM066411; United States / NIEHS NIH HHS / ES / ES011387-04; United States / NIGMS NIH HHS / GM / GM066411-01; United States / NIEHS NIH HHS / ES / U19 ES011387-05S1; United States / NIGMS NIH HHS / GM / GM066411; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NIEHS NIH HHS / ES / ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387; United States / NIGMS NIH HHS / GM / R01 GM066411-01; United States / NIGMS NIH HHS / GM / GM066411-04; United States / NIEHS NIH HHS / ES / U19 ES011387-04; United States / NIEHS NIH HHS / ES / ES011387-03; United States / NIGMS NIH HHS / GM / R01 GM066411-02; United States / NIEHS NIH HHS / ES / U19 ES11387; United States / NIGMS NIH HHS / GM / GM066411-02; United States / NIEHS NIH HHS / ES / ES011387-05S1; United States / NIEHS NIH HHS / ES / U19 ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387-03; United States / NIEHS NIH HHS / ES / ES011387-05; United States / NIGMS NIH HHS / GM / GM066411-03; United States / NIEHS NIH HHS / ES / U19 ES011387-02; United States / NIGMS NIH HHS / GM / R01 GM066411-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 63231-63-0 / RNA; YQE403BP4D / Phenobarbital
  • [Other-IDs] NLM/ NIHMS243113; NLM/ PMC2974173
  •  go-up   go-down


Advertisement
4. Jang HS, Kang KM, Choi BO, Chai GY, Hong SC, Ha WS, Jirtle RL: Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma. World J Gastroenterol; 2008 Mar 7;14(9):1394-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma.
  • AIM: To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy.
  • METHODS: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms.
  • CONCLUSION: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Loss of Heterozygosity / genetics. Receptor, IGF Type 2 / genetics
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Polymorphism, Genetic / genetics. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioessays. 2000 Mar;22(3):274-85 [10684587.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3463-70 [16449974.001]
  • [Cites] Bioessays. 2000 May;22(5):452-9 [10797485.001]
  • [Cites] Semin Cancer Biol. 2000 Jun;10(3):185-200 [10936068.001]
  • [Cites] Cell. 2000 Oct 27;103(3):491-500 [11081635.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):153-4 [11175780.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):388-96 [11262195.001]
  • [Cites] Development. 2001 May;128(10):1881-7 [11311167.001]
  • [Cites] Hum Mol Genet. 2001 Aug 15;10(17):1721-8 [11532981.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2917-21 [11711426.001]
  • [Cites] Hepatology. 2002 May;35(5):1153-63 [11981765.001]
  • [Cites] BMC Cancer. 2002 Jul 30;2:18 [12149131.001]
  • [Cites] Genomics. 1988 Oct;3(3):224-9 [2852162.001]
  • [Cites] Nature. 1991 Jan 3;349(6304):84-7 [1845916.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1907s-1911s [8137310.001]
  • [Cites] Development. 1993 Jul;118(3):731-6 [8076514.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1725-9 [7753549.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):447-9 [7493029.001]
  • [Cites] Oncogene. 1996 May 2;12(9):2003-9 [8649861.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):255-7 [8896552.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1851-4 [9157973.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10351-5 [9294214.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):122-3 [9296483.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):18-24 [10094809.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4063-8 [10435587.001]
  • [Cites] Cell Growth Differ. 1999 Aug;10(8):591-600 [10470859.001]
  • [Cites] World J Gastroenterol. 2005 Jul 7;11(25):3850-4 [15991281.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1572-8 [10734317.001]
  • (PMID = 18322954.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, IGF Type 2
  • [Other-IDs] NLM/ PMC2693688
  •  go-up   go-down


5. Xu K, Luo HY, Li LN: [Clinical study on comprehensive treatment of primary liver cancer mainly with chinese medicinal perfusion/embolization]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Apr;25(4):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on comprehensive treatment of primary liver cancer mainly with chinese medicinal perfusion/embolization].
  • OBJECTIVE: To study the clinical efficacy and adverse reaction of comprehensive therapy mainly with Chinese anti-cancer medicinal perfusion/embolization and assisted with Chinese drug-therapy based on TCM Syndrome Differentiation in treating primary liver cancer.
  • METHODS: Forty-one patients with liver cancer were divided into the treated group and the control group.
  • CONCLUSION: Chinese anti-cancer medicinal perfusion/embolization has affirmative short-term clinical effect in treating primary liver cancer with few adverse reactions, which was tolerable to patients, but its long-term clinical efficacy needs further observation.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892270.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


6. Noguera JJ, Martínez-Cuesta A, Sangro B, Bilbao JI: [Fatal pulmonary embolism after embolization of a hepatocellular carcinoma using microspheres]. Radiologia; 2008 May-Jun;50(3):248-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatal pulmonary embolism after embolization of a hepatocellular carcinoma using microspheres].
  • Intra-arterial treatment has become a first-line alternative in the therapeutic arsenal against primary and metastatic hepatic tumors.
  • We present the case of a 32-year-old woman with multifocal hepatocellular carcinoma treated with microsphere embolization.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic / adverse effects. Liver Neoplasms / therapy. Microspheres. Pulmonary Embolism / etiology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471393.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Scudiere JR, Shi C, Hruban RH, Herman JM, Fishman EK, Schulick RD, Wolfgang CL, Makary MA, Thornton K, Montgomery E, Horton KM: Sclerosing mesenteritis involving the pancreas: a mimicker of pancreatic cancer. Am J Surg Pathol; 2010 Apr;34(4):447-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When SM does involve the pancreas, it can mimic pancreatic carcinoma both clinically and radiographically with pain, obstructive jaundice, a mass lesion, and even the appearance of vascular invasion.
  • Five of these 6 patients were originally thought to have a primary pancreatic neoplasm.
  • Distinguishing SM from pancreatic carcinoma is crucial to appropriate management, as patients with SM may benefit from immunosuppressive therapy.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Sclerosing mesenteritis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2008 Aug;74(8):743-5 [18705578.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):66-70 [18836421.001]
  • [Cites] Acta Radiol. 2008 Sep;49(7):744-6 [19143059.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):427-31 [10658720.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Nov;11(11):1323-9 [10563549.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1296-301 [12360044.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):110-20 [12502933.001]
  • [Cites] Radiographics. 2003 Nov-Dec;23(6):1561-7 [14615565.001]
  • [Cites] Surgery. 1977 Feb;81(2):203-11 [835091.001]
  • [Cites] Dis Colon Rectum. 1987 Dec;30(12):962-6 [3319450.001]
  • [Cites] Dig Dis Sci. 1996 Apr;41(4):684-8 [8674388.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):392-8 [9130985.001]
  • [Cites] Am J Gastroenterol. 1997 Jun;92(6):1059-60 [9177537.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1313-7 [9609769.001]
  • [Cites] Endoscopy. 1998 Oct;30(8):S94-5 [9865579.001]
  • [Cites] AJR Am J Roentgenol. 1999 Mar;172(3):625-9 [10063848.001]
  • [Cites] Pancreas. 1999 Apr;18(3):316-21 [10206491.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1974-7 [15622594.001]
  • [Cites] Australas Radiol. 2005 Feb;49(1):84-7 [15727618.001]
  • [Cites] Radiographics. 2006 Jan-Feb;26(1):245-64 [16418255.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Dec;18(12):1285-7 [17099377.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 May;5(5):589-96; quiz 523-4 [17478346.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Gastrointestin Liver Dis. 2008 Mar;17(1):91-4 [18392253.001]
  • (PMID = 20351487.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062924-149002; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / P50 CA062924-149002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ NIHMS181132; NLM/ PMC2861335
  •  go-up   go-down


8. Lee IJ, Chung JW, Kim HC, Yin YH, So YH, Jeon UB, Jae HJ, Cho BH, Park JH: Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. J Vasc Interv Radiol; 2009 Jan;20(1):22-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors.
  • PURPOSE: To retrospectively evaluate the prevalence of extrahepatic collateral artery supply to tumor thrombi of hepatocellular carcinomas (HCCs) invading the inferior vena cava (IVC) and to assess the determining factors.
  • Potential determining factors for extrahepatic collateral artery supply to the IVC tumor thrombi included sex, age, Child-Pugh class, history of chemoembolization, tumor factors (ie, size, number, and growth pattern), distance from primary tumor to IVC thrombi, portal vein invasion, and extent of IVC thrombi (ie, occupying more than half the IVC lumen on transverse CT image, completely filling and distending IVC lumen, or extending into the right atrium).
  • [MeSH-major] Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / radiography. Collateral Circulation. Liver Circulation. Liver Neoplasms / blood supply. Liver Neoplasms / radiography. Vena Cava, Inferior / radiography
  • [MeSH-minor] Adolescent. Adrenal Glands / blood supply. Adult. Aged. Chemoembolization, Therapeutic / adverse effects. Diaphragm / blood supply. Female. Humans. Logistic Models. Male. Mammary Arteries / radiography. Middle Aged. Neoplasm Invasiveness. Registries. Renal Artery / radiography. Retrospective Studies. Risk Assessment. Risk Factors. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19026566.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Idasiak A, Masłyk B, Blamek S, Suwiński R: [Risk of distant metastases after postoperative radiation therapy for locally advanced laryngeal cancer]. Otolaryngol Pol; 2008;62(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts had locally advanced squamous cell laryngeal cancer treated with surgery and postoperative radiotherapy.
  • The lungs and bones were the most common sites of metastases (58% and 33% respectively), whereas metastases to liver (6%) and brain (3%) were rare.
  • CONCLUSIONS: Number of positive lymph nodes in pathological specimen and site of primary cancer (glottic vs. supraglottic) significantly and independently predict a risk of distant metastases in combined modality treatment for laryngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Incidence. Laryngectomy / statistics & numerical data. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Poland / epidemiology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637438.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Massironi S, Conte D, Sciola V, Pirola L, Paggi S, Fraquelli M, Ciafardini C, Spampatti MP, Peracchi M: Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours. Dig Liver Dis; 2010 Sep;42(9):635-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eighteen out of 62 GEP NET patients examined between January 2007 and September 2008 had histologically proven hepatic metastases from primary ileal (#6), gastric (#1) or rectal (#1) carcinoids, pancreatic tumours (#7), or primary duodenal (#2) or occult gastrinomas (#1), and all underwent low mechanical index real-time CEUS with SonoVue injection.
  • CONCLUSIONS: Most of the neuroendocrine liver metastases showed increased arterial enhancement at CEUS, a behaviour that is similar to that of hepatocellular carcinomas and the opposite of that of other metastases.
  • [MeSH-major] Carcinoma, Neuroendocrine / ultrasonography. Contrast Media. Gastrointestinal Neoplasms / ultrasonography. Liver Neoplasms / blood supply. Liver Neoplasms / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20172770.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


11. Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V: Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol; 2010;5:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stool consistency and white and red blood cell count in stool were also assessed.
  • The primary endpoint was to reduce the incidence of diarrhea, defined by a CTC grade 2 or more, and the need for anti-diarrheal medication.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Double-Blind Method. Female. Humans. Incidence. Middle Aged. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Placebos. Probiotics / therapeutic use. Prospective Studies. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Treatment Outcome. Young Adult


12. Lee HL, Liu YY, Yeh CN, Chiang KC, Chen TC, Jan YY: Primary squamous cell carcinoma of the liver: a successful surgically treated case. World J Gastroenterol; 2006 Sep 7;12(33):5419-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the liver: a successful surgically treated case.
  • Primary squamous cell carcinoma (SCC) of the liver is rare.
  • Primary SCC of the liver has been reported to be associated with hepatic teratoma, hepatic cyst, or hepatolithiasis.
  • Complete remission of poorly differentiated SCC of the liver could be achieved by systemic chemotherapy followed by surgery or remarkably respond to hepatic arterial injection of low dose chemotherapeutic drugs.
  • Here we report the first case of primary SCC of the liver presenting as a solid tumor and receiving successful hepatic resection with 9-mo disease free survival.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Liver / pathology. Liver / ultrasonography. Male. Remission Induction. Treatment Outcome. Ultrasonography


13. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC: Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res; 2006 Mar 1;12(5):1412-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
  • PURPOSE: The deleted in liver cancer-1 (DLC-1) gene that encodes a Rho GTPase-activating protein with tumor suppressor function is located on chromosome 8p21-22, a region frequently deleted in prostate carcinomas.
  • EXPERIMENTAL DESIGN: Primary prostate carcinomas, prostate carcinoma cell lines, benign prostatic hyperplasias, and normal prostatic tissues were examined for detection of functional and structural alterations of the DLC-1 gene by real-time PCR, methylation-specific PCR, and Southern and Western blots.
  • RESULTS: Down-regulation or loss of DCL-1 mRNA expression was detected in 10 of 27 (37%) prostate carcinomas, 3 of 5 (60%) prostate carcinoma cell lines, and 5 of 21 (24%) benign prostatic hyperplasias.
  • Methylation of DLC-1 correlated with age in prostate carcinoma patients (P = 0.006) and with prostate-specific antigen blood levels in benign prostatic hyperplasia patients (P = 0.029).
  • Treatment of the three prostate carcinoma cell lines (PC-3, LNCaP, and 22Rv1) expressing a low level of DLC-1 transcripts with inhibitors of DNA methyltransferase or histone deacetylase increased DLC-1 expression.
  • [MeSH-minor] Acetylation. Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Base Sequence. Blotting, Southern. Blotting, Western. Chromatin Immunoprecipitation. Down-Regulation. Enzyme Inhibitors / pharmacology. GTPase-Activating Proteins. Humans. Male. Middle Aged. Molecular Sequence Data. Promoter Regions, Genetic / genetics. Prostate / metabolism. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533763.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DLC1 protein, human; 0 / Enzyme Inhibitors; 0 / GTPase-Activating Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


14. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol; 2005 Nov;174(5):1759-63; discussion 1763
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
  • PURPOSE: We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC).
  • MATERIALS AND METHODS: We studied 727 patients treated with radical nephrectomy for clear cell RCC from 1970 to 2000 who had distant metastases at nephrectomy (285) or in whom metastases subsequently developed (442).
  • RESULTS: There were 606 deaths from clear cell RCC at a median of 1.0 years (range 0 to 14) following metastatic RCC.
  • Constitutional symptoms at nephrectomy (+2), metastases to the bone (+2) or liver (+4), metastases in multiple simultaneous sites (+2), metastases at nephrectomy (+1) or within 2 years of nephrectomy (+3), complete resection of all metastatic sites (-5), tumor thrombus level I to IV (+3), and the primary pathological features of nuclear grade 4 (+3) and histological tumor necrosis (+2) were significantly associated with death from RCC.
  • CONCLUSIONS: This scoring algorithm can be used to predict cancer specific survival for patients with metastatic clear cell RCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Algorithms. Carcinoma, Renal Cell / mortality. Cause of Death. Kidney Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Clinical Trials as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Nephrectomy / methods. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis


15. Lin G, Toh CH, Wu RC, Ko SF, Ng SH, Chou WC, Tseng JH: Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging. Int J Clin Pract; 2008 Aug;62(8):1199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.
  • This study was designed to assess the clinical usefulness of imaging for predicting the prognosis of patients with combined hepatocellular cholangiocarcinoma (cHCC-CC).
  • Analysing the survival of our patients by using clinical stages of the newly updated American Joint Committee on Cancer (AJCC) classification for liver neoplasm based on the imaging findings, we found significant differences between stages I/II and III (p < 0.001) and between stages III and IV (p = 0.040).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Magnetic Resonance Imaging / standards. Neoplasms, Multiple Primary / pathology. Tomography, X-Ray Computed / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537192.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, Moriya T, Simpson ER, Sasano H, Clyne CD: Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res; 2005 Jan 15;65(2):657-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer.
  • Recently, the orphan nuclear receptor, liver receptor homologue-1 (LRH-1), has also been shown to regulate aromatase expression in breast adipose tissue.
  • We therefore examined the expression of, and correlations between, aromatase and LRH-1 mRNA in a panel of breast carcinoma tissues and adjacent adipose tissue.
  • LRH-1 mRNA expression was low in normal breast tissue but markedly elevated in both breast carcinoma tissue and adipose tissue surrounding the tumor invasion (thereby paralleling aromatase expression).
  • Ectopic expression of LRH-1 in primary human adipose stromal cells strongly activated endogenous aromatase mRNA expression and enzyme activity.
  • [MeSH-minor] Adipose Tissue / cytology. Adipose Tissue / drug effects. Adipose Tissue / enzymology. Adipose Tissue / metabolism. Adult. Aged. Enzyme Induction / drug effects. Female. Humans. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Stromal Cells / drug effects. Stromal Cells / enzymology. Stromal Cells / metabolism. Transcription Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695411.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / NR5A2 protein, human; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Transcription Factors; EC 1.14.14.1 / Aromatase; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


17. Chao SD, Roberts JP, Farr M, Yao FY: Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant; 2007 Jun;7(6):1594-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma.
  • It has been suggested that patients with hepatocellular carcinoma (HCC) undergoing living donor liver transplantation (LDLT) have worse recurrence-free survival compared to deceased donor liver transplantation (CLT), leading to the hypothesis that short waitlist time or fast-tracking may include more aggressive tumors that would have been selected out by traditionally longer waitlist time.
  • The primary aim of the present study was to evaluate the impact of waitlist time on HCC recurrence.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Transplantation. Tissue Donors / statistics & numerical data. Waiting Lists
  • [MeSH-minor] Adult. Aged. Cadaver. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Male. Middle Aged. Probability. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430396.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30DK26743
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  •  go-up   go-down


18. Wang ZP, Liu YT, Yang J: [Classification and regression tree analysis of 154 patients with cancer of unknown primary]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):690-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classification and regression tree analysis of 154 patients with cancer of unknown primary].
  • OBJECTIVE: To explore the prognostic factors and their impact on survival of patients with cancer of unknown primary (CUP).
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Neoplasms, Unknown Primary / classification
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Regression Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122385.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP: Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology; 2009 Mar;49(3):821-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.
  • Wnt/beta-catenin signaling plays an important role in liver development and regeneration.
  • Its aberrant activation, however, is observed in a subset of primary hepatocellular cancers (HCCs).

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):143-50 [18577996.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):703-10 [10487827.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):239-48 [15471898.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3619-31 [15782138.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1417-23 [15920538.001]
  • [Cites] Cell Tissue Res. 2006 Jan;323(1):71-9 [16160859.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):410-4 [16564914.001]
  • [Cites] Hepatology. 2006 Apr;43(4):817-25 [16557553.001]
  • [Cites] Hepatology. 2006 Mar;43(3):515-24 [16496320.001]
  • [Cites] Nat Med. 2006 Apr;12(4):410-6 [16532004.001]
  • [Cites] Dev Cell. 2006 Jun;10(6):759-70 [16740478.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):245-50 [10700176.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):357-61 [10888422.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1671-7 [11245482.001]
  • [Cites] Hepatology. 2001 May;33(5):1098-109 [11343237.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1763-73 [11375957.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1527-36 [11896101.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4863-71 [12101426.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5685-8 [12384525.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):44-50 [15305374.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] J Cell Biol. 1996 Mar;132(6):1133-49 [8601590.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3778-86 [16799619.001]
  • [Cites] Exp Cell Res. 2006 Nov 1;312(18):3620-30 [16952352.001]
  • [Cites] J Surg Res. 2006 Nov;136(1):125-35 [17023002.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1561-72 [17101329.001]
  • [Cites] Hepatology. 2007 Jan;45(1):42-52 [17187432.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):774-80 [16964294.001]
  • [Cites] Hepatology. 2007 Feb;45(2):361-8 [17256747.001]
  • [Cites] J Hepatol. 2007 May;46(5):849-57 [17275129.001]
  • [Cites] Hepatology. 2007 May;45(5):1298-305 [17464972.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8 [17481532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6 [17785413.001]
  • [Cites] Hepatology. 2007 Sep;46(3):740-8 [17663417.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1579-91 [17983805.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10831-9 [18006828.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):951-9 [18030363.001]
  • [Cites] Hepatology. 2008 Jan;47(1):288-95 [17929301.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jan;23(1):110-8 [18171349.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1451-61 [18316609.001]
  • [Cites] J Hepatol. 2008 May;48(5):780-91 [18313787.001]
  • [Cites] Mol Cancer. 2008;7:21 [18282277.001]
  • [Cites] Hepatology. 2008 May;47(5):1667-79 [18393386.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4287-95 [18519688.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jul;67(1):8-15 [18434184.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2800-5 [18539957.001]
  • [Cites] J Gastroenterol. 2008;43(5):378-89 [18592156.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • (PMID = 19101982.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA124414; United States / NCI NIH HHS / CA / R01 CA124414; United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NCI NIH HHS / CA / R01 CA124414-02; United States / NCI NIH HHS / CA / CA124414-02; United States / NIDDK NIH HHS / DK / 1R01DK62277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 6.3.1.2 / Glutamate-Ammonia Ligase
  • [Other-IDs] NLM/ NIHMS95668; NLM/ PMC2657345
  •  go-up   go-down


20. Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, Qin LX, Turlin B, Tang ZY, Mazzaferro V, Dejean A: Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res; 2008 May 31;653(1-2):6-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure.
  • Hepatocellular carcinoma (HCC) is a heterogeneous disease triggered by various risk factors and frequently characterized by chromosome instability.
  • We studied 90 HCCs from Italy, the country with the highest incidence of hepatocellular carcinoma in Europe, 81 samples from France and 52 specimens from Shanghai, in a region where intake of AFB1 via the diet is known to be high.
  • We suggest that AFB1-associated mutagenesis represents a plausible cause for the higher chromosome instability observed in Chinese HCCs, when compared with European primary liver carcinomas.
  • [MeSH-major] Aflatoxin B1 / toxicity. Carcinoma, Hepatocellular / chemically induced. Carcinoma, Hepatocellular / genetics. Chromosomal Instability / drug effects. Mutagens / toxicity. Mutation, Missense. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Substitution. Asian Continental Ancestry Group. China. Chromosomes, Human, Pair 13 / genetics. European Continental Ancestry Group. Female. France. Hepatitis B / complications. Hepatitis B / genetics. Hepatitis B virus. Humans. Italy. Loss of Heterozygosity / drug effects. Loss of Heterozygosity / genetics. Male. Middle Aged. Poisons / toxicity. Risk Factors. beta Catenin / genetics

  • Hazardous Substances Data Bank. AFLATOXIN B1 .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467159.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Mutagens; 0 / Poisons; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; 9N2N2Y55MH / Aflatoxin B1
  •  go-up   go-down


21. Kim W, Lee JH, Kim YJ, Yoon JH, Suh KS, Lee KU, Jang JJ, Lee HS: [Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma]. Korean J Gastroenterol; 2007 Mar;49(3):158-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma].
  • BACKGROUND/AIMS: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare form of primary liver carcinoma which contains characteristics of both hepatocellular carcinoma and cholangiocarcinoma.
  • However, surgical treatment should be warranted for relatively young patients in early stage with well preserved liver function.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / mortality. Cholangiocarcinoma / mortality. Liver Neoplasms / mortality. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Severity of Illness Index. Survival Analysis. Tomography, X-Ray Computed


22. Alvarez-Múgica M, Bulnes Vázquez V, Jalón Monzón A, Gil A, Rodríguez Robles L, Miranda Aranzubía O: Late recurrence from a renal cell carcinoma: solitary right maxilar mass 17 years after surgery. Arch Esp Urol; 2010 Mar;63(2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence from a renal cell carcinoma: solitary right maxilar mass 17 years after surgery.
  • OBJECTIVES: To report a new case of late renal cell carcinoma recurrence.
  • METHODS: Renal cell carcinoma represents approximately 3% of all adult malignancies.
  • The most frequent metastatic sites are lung (76%), regional lymph nodes (66%), bone (42%), and liver (41%), and it is the third most common infraclavicular neoplasm to metastasize to head and neck.
  • The histological diagnosis of the referred mass was clear cell carcinoma.
  • Examination under general anaesthesia and biopsy was performed revealing metastasis of a renal cell carcinoma.
  • CONCLUSIONS: The natural history of renal cell carcinoma is highly variable, metastases may present decades after the removal of the primary disease, however, only 1% of patients with renal cell carcinoma have metastases confined only to the head and neck, and solitary cervical metastatic mass is rare.
  • Moreover, renal cell carcinoma should be considered in the differential diagnosis of any growing lesion in the head and neck.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Maxillary Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378937.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


23. Ikeda S: [Adult-onset citrullinemia]. Brain Nerve; 2007 Jan;59(1):59-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset citrullinemia].
  • Adult-onset citrullinemia (CTLN2) is a rare hereditary metabolic disorder characterized by highly increased concentration of citrulline and ammonia in the plasma, which is ascribed to a deficiency of argininosuccinate synthetase (ASS), one of the urea cycle enzymes mainly located in the liver.
  • However, in 1995 the first CTLN2 patient who was successfully treated by living-related liver transplantation was reported and since then more than 30 patients had underwent this operation in our country, showing good outcomes.
  • No primary defect had not been found within ASS gene locus, but the causative gene of this disorder is now identified as the "citrin gene", which might act as a aspartate/glutamate transporter in mitochondria.
  • Different phenotypes are seen in the individuals with a citrin deficiency: neonatal intrahepatic cholestasis, juvenile-onset chronic pancreatitis and hepatocellular carcinoma without cirrhosis can precede the appearance of CTLN2.
  • [MeSH-minor] Administration, Oral. Adult. Age of Onset. Arginine / administration & dosage. Argininosuccinate Synthase. Calcium-Binding Proteins / genetics. Cholestasis, Intrahepatic / etiology. Chronic Disease. Glycerol / contraindications. Humans. Liver Neoplasms / etiology. Liver Transplantation. Mutation. Organic Anion Transporters / genetics. Pancreatitis / etiology. Phenotype

  • Genetic Alliance. consumer health - Citrullinemia.
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354380.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Organic Anion Transporters; 1340-08-5 / citrin; 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase; PDC6A3C0OX / Glycerol
  • [Number-of-references] 34
  •  go-up   go-down


24. Melloni G, Doglioni C, Bandiera A, Carretta A, Ciriaco P, Arrigoni G, Zannini P: Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma. Ann Thorac Surg; 2006 Jun;81(6):2008-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
  • BACKGROUND: In this study, we analyze our experience with pulmonary resection for metastases from colorectal carcinoma.
  • The aims were to search for factors influencing prognosis and to investigate the presence of microsatellite instability in the primary tumors and the corresponding lung metastases.
  • The microsatellite instability was determined by immunohistochemical evaluation of MSH2 and MLH1 in 117 lesions (41 primary tumors and 76 lung metastases).
  • Univariate analysis showed that stage of the primary tumor (p = 0.037), radicalness of the resection (p = 0.019), and stratification into groups according to the International Registry of Lung Metastases classification (p = 0.039) were prognostic factors.
  • Multivariate analysis showed that stage of the primary tumor (p = 0.030) and the radicalness of the resection (p = 0.014) were independent prognostic factors.
  • CONCLUSIONS: Pulmonary resection of metastases from colorectal carcinoma results in long-term survival in selected patients.
  • Complete resection, stage of the primary tumor and stratification into groups according to the International Registry of Lung Metastases classification were prognostic factors.
  • All the metastases and the corresponding primary tumors were microsatellite stable lesions.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Life Tables. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731121.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol; 2009 Mar;16(3):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
  • BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types.
  • PATIENTS AND METHODS: Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor.
  • CONCLUSIONS: Patients with combined hepatocellular carcinoma and cholangiocarcinoma had poor postoperative survival rates.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Transplantation. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130133.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. McMahon BJ: Implementing evidenced-based practice guidelines for the management of chronic hepatitis B virus infection. Am J Med; 2008 Dec;121(12 Suppl):S45-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this article is to take the recommendations from these documents and help guide clinicians--whether they are primary care providers, hepatologists, gastroenterologists, or public health workers--about how to incorporate these guidelines into practice.
  • In addition, alpha-fetoprotein should be tested and ultrasound performed on all men aged >40 years and women >50 years of age to detect any hepatocellular carcinoma (HCC) in an early stage.
  • Algorithms are included for primary care providers providing information on initial evaluation and management and referral of persons with CHB, and for specialists evaluating and treating HBV.
  • Implementing steps to identify, follow, refer, and treat appropriately persons with CHB infection by all primary care and specialist healthcare providers can have a major impact on reducing the occurrence of HCC and cirrhosis in infected persons.
  • [MeSH-minor] Adult. Algorithms. Female. Humans. Male. Middle Aged. Serologic Tests

  • Genetic Alliance. consumer health - Hepatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185074.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


27. Huang XW, Zhao Q, Chen DZ, Zhang LS: [Mutations in the D-loop region of mitochondrial DNA and the ROS level in the tissue of hepatocellular carcinoma]. Yi Chuan; 2005 Jan;27(1):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutations in the D-loop region of mitochondrial DNA and the ROS level in the tissue of hepatocellular carcinoma].
  • To explore the relationship between ROS level and mutations in D-Loop region of mtDNA, mutations in the D-Loop region of mtDNA and the ROS level in primary hepatocarcinoma tissues were studied.
  • It was concluded that the D-Loop region of mitochondrial DNA was a highly polymorphoric and mutable region and mutation rate was relatively high in patients with hepaticellular carcinoma, and the abnormal ROS level might be the point mutation in the mitochondrial DNA and hepatocarcinogenesis related to ROS.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730952.001).
  • [ISSN] 0253-9772
  • [Journal-full-title] Yi chuan = Hereditas
  • [ISO-abbreviation] Yi Chuan
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Reactive Oxygen Species
  •  go-up   go-down


28. Przybyłowski T, Krenke R, Fangrat A, Nasilowski J, Grabczak EM, Styczynski G, Pruszczyk P, Krawczyk M, Chazan R: Gas exchange abnormalities in patients listed for liver transplantation. J Physiol Pharmacol; 2006 Sep;57 Suppl 4:313-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gas exchange abnormalities in patients listed for liver transplantation.
  • Abnormalities of pulmonary gas exchange are common in patients with advanced liver disease.
  • Since arterial blood hypoxemia is an important issue in the preoperative evaluation of liver transplant candidates, the study was undertaken to determine the incidence and severity of lung function impairment with a special emphasis on pulmonary gas exchange abnormalities in this group of patients.
  • 104 consecutive patients (47 F and 57 M, mean age 46 +/-11 yr) listed for orthotopic liver transplantation participated in this prospective study.
  • There were 2 patients with acute hepatic failure, 6 patients with primary or metastatic liver carcinoma, and 96 patients with chronic liver disease.
  • [MeSH-major] Hepatopulmonary Syndrome / blood. Liver Diseases / blood. Liver Transplantation. Pulmonary Gas Exchange
  • [MeSH-minor] Adult. Blood Gas Analysis. Echocardiography. Female. Humans. Lung / physiopathology. Lung / radiography. Male. Middle Aged. Respiratory Function Tests

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072060.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


29. Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y, Nomura F, Gonda H, Imaizumi K, Hasegawa Y, Shimokata K: A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer; 2009 Jan;63(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-four patients with stage IIIB or IV non-small cell lung cancer (NSCLC), Eastern Cooperative Oncology Group performance status (PS) 0 or 1, who had adequate organ function, were eligible.
  • The response rate was the primary endpoint.
  • As for non-hematological toxicities, one case of G4 toxicity (perforation of jejunum) was observed, but other toxicities were mild (one muscle pain, two liver dysfunction, one fatigue and one nausea G3).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / administration & dosage. Thiazines / administration & dosage. Thiazoles / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Quality of Life. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. Meloxicam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499296.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Thiazines; 0 / Thiazoles; 71125-38-7 / meloxicam; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Xu Y, DU WJ, Qin LY, Xing ZZ, Qin XH, Chen SJ: [Expression of interleukin-17 in hepatitis B related liver fibrosis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Feb;25(2):133-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of interleukin-17 in hepatitis B related liver fibrosis].
  • AIM: To explore the role of interleukin-17 (IL-17) in the pathogenesis and progress of chronic hepatitis B virus (HBV) related liver diseases, especially in hepatitis B related liver fibrosis.
  • METHODS: Whole vein blood was obtained from the patients with chronic hepatitis B (CHB) (n=36), liver cirrhosis (LC) (n=42) including child-pugh A (n=15), child-pugh B (n=12), child-pugh C (n=15), primary hepatitis carcinoma (PHC) (n=34), chronic severe hepatitis (n=30) and normal control (n=20).The level of serum IL-17 and the expression of IL-17 mRNA in peripheral blood mononuclear cell (PBMC) were analysed by ELISA and RT-PCR respectively.
  • Serum IL-17 and liver fibrosis index (C-IV, LN, HA) concentration of LC classified by child-pugh scores were detected by ELISA.
  • The level of serum IL-17 and liver fibrosis index in child-pugh C group in LC patients were higher than that in Child-pugh B group and that in child-pugh B group were higher than that in child-pugh A group (P<0.01).
  • The level of serum IL-17 in LC group positively correlated to child-pugh score and liver fibrosis index (C-IV, LN, HA) (r=0.582, 0.568, 0.682, 0.764, P<0.01).
  • CONCLUSION: IL-17 is obviously increased in HBV related liver diseases, especially in hepatitis B related liver cirrhosis, indicating that IL-17 may play a part in the development of HBV related liver diseases, especially the pathophysiology of hepatitis B related liver fibrosis.
  • [MeSH-major] Hepatitis B / complications. Interleukin-17 / metabolism. Liver Cirrhosis / metabolism
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Liver Diseases / etiology. Liver Diseases / metabolism. Liver Diseases / virology. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174010.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-17
  •  go-up   go-down


31. Mixich F, Ioana M, Voinea F, Săftoiu A, Ciurea T: Noninvasive detection through REMS-PCR technique of K-ras mutations in stool DNA of patients with colorectal cancer. J Gastrointestin Liver Dis; 2007 Mar;16(1):5-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Paired stool and tissue specimens obtained after polypectomy and colorectal biopsy from 28 patients diagnosed solely by histopathological findings with primary colorectal carcinoma, were prospectively studied for K-ras codon 12 mutations by restriction endonuclease-mediated selective (REMS)-PCR.
  • CONCLUSIONS: The sensitivity and specificity of K-ras determination on stool-derived DNA in patients with colorectal carcinoma, support the opportunity of a large-scale trial to validate its use as a screening test.
  • [MeSH-major] Carcinoma / genetics. Colorectal Neoplasms / genetics. Feces. Genes, ras / genetics. Mutation / genetics. Polymerase Chain Reaction. Restriction Mapping
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged


32. Felici A, Di Segni S, Milella M, Colantonio S, Sperduti I, Nuvoli B, Contestabile M, Sacconi A, Zaratti M, Citro G, Cognetti F: Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. Clin Pharmacokinet; 2009;48(2):131-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary aim of this study was to evaluate the pharmacokinetics of dFdC and its metabolite difluorodeoxyuridine (dFdU) in patients with normal and impaired hepatic function.
  • PATIENTS AND METHODS: In this prospective study, patients with pancreatic or biliary tract carcinoma and normal or impaired hepatic function tests were considered eligible for recruitment.
  • [MeSH-major] Adenocarcinoma / blood. Antimetabolites, Antineoplastic / pharmacokinetics. Biliary Tract Neoplasms / blood. Deoxycytidine / analogs & derivatives. Liver Diseases / blood. Pancreatic Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Area Under Curve. Chromatography, High Pressure Liquid. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Floxuridine / analogs & derivatives. Floxuridine / pharmacokinetics. Humans. Infusions, Intravenous. Liver Function Tests. Male. Middle Aged. Prospective Studies. Tandem Mass Spectrometry

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):258-62 [1998982.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5704-9 [18089865.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1237-45 [16078261.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2780-7 [10894879.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1128-33 [16670205.001]
  • [Cites] Invest New Drugs. 1997;15(4):331-41 [9547676.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3441-5 [9396395.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] Mol Pharmacol. 1990 Oct;38(4):567-72 [2233693.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5691-4 [18089862.001]
  • [Cites] Ann Oncol. 1994 May;5(5):471-2 [8075055.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4024-31 [3383195.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):310-6 [8996158.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3394-8 [9363871.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6823-6 [2208147.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(10):1017-23 [15150823.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):919-27 [12123338.001]
  • (PMID = 19271785.001).
  • [ISSN] 0312-5963
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 2',2'-difluoro-2'-deoxyuridine; 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


33. Liu YB, Gao SL, Chen XP, Peng SY, Fang HQ, Wu YL, Peng CH, Tang Z, Xu B, Wang JW, Deng GL, Li HJ, Feng XD, Qian HR: Expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma. World J Gastroenterol; 2005 Mar 7;11(9):1378-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma.
  • AIM: To explore the relation between heparanase (HPA) and nm23-H1 in hepatocellular carcinoma (HCC), and whether they could be used as valuable markers in predicting post-operative metastasis and recurrence of HCC.
  • METHODS: Reverse transcription-polymerase chain reaction and immunohistochemistry (S-P method) were used to measure the expressions of HPA mRNA and nm23-H1 protein in primary tumor tissue and paracancerous tissue of 33 cases of HCC.
  • Paracancerous tissues of 9 cases of benign liver tumor were used as normal controls.
  • RESULTS: The positive expression of HPA gene was significantly higher in primary tumor tissues of HCC (48.5%, 16/33) as compared to the paracancerous tissues of HCC and normal controls (3.03%, 1/33) (P < 0.01).
  • HPA expression was not related with the size of tumor, envelope formation, AFP level, HBsAg state and cirrhosis of liver.
  • The positive expression rate of nm23-H1 protein in HCC tissue was significantly lower than that in corresponding non-cancerous or normal liver tissue (45.5, 72.7, 88.9%, P < 0.05).
  • nm23-H1 expression was not related with the size of tumor, envelope formation, AFP level, HBsAg state, cirrhosis of liver, Edmondson grade, and TNM stage (P > 0.05).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / secondary. Glucuronidase / genetics. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Nucleoside-Diphosphate Kinase / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. NM23 Nucleoside Diphosphate Kinases. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Postoperative Complications. Predictive Value of Tests. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761980.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  • [Other-IDs] NLM/ PMC4250689
  •  go-up   go-down


34. Lai MS, Hsieh MS, Chiu YH, Chen TH: Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology; 2006 Jun;43(6):1295-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection.
  • This study aimed to elucidate the relationship of type 2 diabetes, other known risk factors, and primary hepatocellular carcinoma (HCC) in countries with a high prevalence of hepatitis infection.
  • A total of 5,732 subjects with type 2 diabetes cases were identified at enrollment on the basis of fasting blood glucose level, and a total of 138 confirmed HCC cases were identified either through two-stage liver cancer screening or linkage with the National Cancer Registry.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Diabetes Mellitus, Type 2 / epidemiology. Hepatitis C, Chronic / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Comorbidity. Endemic Diseases. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prevalence. Probability. Proportional Hazards Models. Prospective Studies. Severity of Illness Index. Sex Distribution. Survival Rate. Taiwan / epidemiology


35. Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol; 2009 Mar;24(3):346-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in the Asia pacific region.
  • Primary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide.
  • In spite of advances in surgery, liver transplantation and newer pharmaco/biological therapies, the survival rate has improved only slightly over recent decades, and this could be attributable to earlier diagnosis ('lead-time bias').
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Asia / epidemiology. Asian Continental Ancestry Group. Female. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Male. Middle Aged. Odds Ratio. Prevalence. Prognosis. Risk Assessment. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220670.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 35
  • [Investigator] Farrell GC; Chan HL; Yuen MF; Amarapurkar DN; Chutaputti A; Fan JG; Hou JL; Han KH; Kao JH; Lim SG; Mohamed R; Sollano J; Ueno Y
  •  go-up   go-down


36. Lee MW, Lee JY, Kim YJ, Park EA, Choi JY, Kim SH, Lee JM, Han JK, Choi BI: Gastric hepatoid adenocarcinoma: CT findings. Abdom Imaging; 2007 May-Jun;32(3):293-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adjacent organ invasions were noted to liver (n = 3), pancreas (n = 2), and esophagus (n = 1).
  • Distant metastases (liver, n = 4; non-regional lymph node, n = 1) were also noted.
  • Venous tumor thrombosis was identified in the portal vein (n = 3), splenic vein (n = 1), main portal vein (n = 1), or right gastroepiploic vein (n = 1) in the regions near primary gastric tumors or metastatic masses.
  • CONCLUSION: On CT scans, hepatoid adenocarcinoma of the stomach appears as an eccentric gastric wall thickening and shows a strong tendency for liver and lymph node metastasis and venous invasion around the primary gastric tumor or a metastatic hepatic mass.
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967243.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Malouf G, Falissard B, Azoulay D, Callea F, Ferrell LD, Goodman ZD, Hayashi Y, Hsu HC, Hubscher SG, Kojiro M, Ng IO, Paterson AC, Reynes M, Zafrani ES, Emile JF: Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol; 2009 Jun;62(6):519-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts?
  • Little is known about the reproducibility of the pathological diagnosis of primary liver carcinomas.
  • Therefore, this study aimed to evaluate the worldwide variation in the pathological expert diagnoses of primary liver carcinomas with fibrous stroma in patients who did not have cirrhosis.
  • METHODS: A single set of slides was selected from 25 tumours, and this set was reviewed independently by 12 pathologists who have worldwide expertise in liver tumours.
  • RESULTS: The interobserver reproducibility for diagnosis of hepatocellular carcinoma subtypes and cholangiocarcinomas was poor (kappa 0.23-0.52), even when the experts considered that the diagnosis required no additional stains or clinical information.
  • Interestingly, multidimensional scaling revealed three main clusters of tumours: hepatocellular carcinoma with no other specifications (n = 13), fibrolamellar hepatocellular carcinoma (n = 3) and cholangiocarcinoma (n = 9).
  • CONCLUSIONS: The results demonstrate the poor reproducibility among experts of the pathological diagnosis of primary liver carcinomas with fibrous stroma in patients who did not have cirrhosis, and highlight that the systematic use of immunohistochemistry may improve the diagnostic accuracy.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Medical Oncology / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies / analysis. Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / immunology. Child. Cluster Analysis. Diagnosis, Differential. Female. Hepatocytes / pathology. Humans. Immunohistochemistry. Keratin-19 / immunology. Keratin-7 / immunology. Keratins / analysis. Male. Middle Aged. Reproducibility of Results. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155239.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


38. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer; 2007 Apr 1;120(7):1444-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.
  • Recently increasing reported data have suggested that only a small subset of cancer cells possess capability to initiate malignancies including leukemia and solid tumors, which was based on investigation in these cells displaying a distinct surface marker pattern within the primary cancers.
  • CD133 is a putative hematopoietic and neuronal stem-cell marker, which was also considered as a tumorigenic marker in brain and prostate cancer.
  • We hypothesized that CD133 was a marker closely correlated with tumorigenicity, since it was reported that CD133 expressed in human fetal liver and repairing liver tissues, which tightly associated with hepatocarcinogenesis.
  • Our findings showed that a small population of CD133 positive cells indeed exists in human hepatocellular carcinoma (HCC) cell lines and primary HCC tissues.
  • From SMMC-7721 cell line, CD133+ cells isolated by MACS manifested high tumorigenecity and clonogenicity as compared with CD133- HCC cells.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma, Hepatocellular / metabolism. Glycoproteins / metabolism. Liver Neoplasms / metabolism. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Liver Cirrhosis / metabolism. Male. Mice. Mice, Congenic. Mice, Inbred NOD. Mice, SCID. Middle Aged. Neoplasm Proteins / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17205516.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Peptides
  •  go-up   go-down


39. Ikeda O, Kusunoki S, Nakaura T, Shiraishi S, Kawanaka K, Tomiguchi S, Yamashita Y, Takamori H, Chikamoto A, Kanemitsu K: Comparison of fusion imaging using a combined SPECT/CT system and intra-arterial CT: assessment of drug distribution by an implantable port system in patients undergoing hepatic arterial infusion chemotherapy. Cardiovasc Intervent Radiol; 2006 May-Jun;29(3):371-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic arterial infusion (HAI) chemotherapy is effective for treating primary and metastatic carcinoma of the liver.
  • We studied 28 patients with primary or metastatic carcinoma of the liver who bore an implantable HAI port system.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Liver Neoplasms / drug therapy. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Catheters, Indwelling. Female. Hepatic Artery / radiography. Hepatic Artery / radionuclide imaging. Humans. Image Processing, Computer-Assisted. Infusions, Intra-Arterial. Male. Middle Aged. Prospective Studies. Radiopharmaceuticals / pharmacokinetics. Stomach Diseases / chemically induced. Technetium Tc 99m Aggregated Albumin / pharmacokinetics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16502168.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin
  •  go-up   go-down


40. Díte P, Husová L, Lukás Z, Precechtelová M, Stepánková S: [Immunoglobulin G4-associated cholangitis]. Vnitr Lek; 2010 Aug;56(8):824-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune LgG4- associated cholangitis is a new entity among the liver and biliary tree disorders, classified among the so-called IgG4-related diseases.
  • Even though prognosis of this disease is unclear, this type of sclerosing cholangitis is not being linked to a carcinoma.
  • Clinical and laboratory data differ slightly from the findings associated with the usual primary sclerosing cholangitis and it is mainly the high IgG4 level and hyperbilirubinaemia that supports the diagnosis ofautoimmune disease.
  • Unlike primary sclerosing cholangitis, this disease is not associated with a malignant prognosis and steroids represent an effective treatment.
  • This disease should always be considered as part of differential diagnosis of primary sclerosing cholangitis, especially when autoimmune aberrations or other autoimmune diseases are present.
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845614.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


41. Chen Y, Lin YY, Hu MH, Chen YS: [Clinical research of AFP variant with microcentrifugalcolumn method and crossed affinity immunoelectrophoresis autoradiography method]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Oct;22(5):379-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the clinical value of microcentrifugalcolumn method with crossed affinity immunoelectrophoresis autoradiography method for the measurement of alpha-fetoprotein variant (AFP-L3) in differentiation of benign and malignant liver.
  • METHODS: Serum AFP-L3 variants in 102 primary hepatocellular carcinoma patients and 41 chronic and cirrhosis patients were separated by microcentrifugalcolumn method and crossed affinity immunoelectrophoresis autoradiography method and the clinical value of both method were compared.
  • RESULTS: In 102 primary hepatocellular carcinoma patients, the sensitivity of AFP-L3 was 79.4% and 91.2% respectively, in 41 chronic and cirrhosis patients.
  • In the 4 primary hepatocellular carcinoma patients with lower AFP-L3, the AFP-L3 was positive by useing microcentrifugalcolumn method, but none of AFP-L3 were found by useing crossed affinity immunoelectrophoresis autoradiography method.
  • CONCLUSION: The micro centrifugalcolumn method is more simple and rapid, it may be more useful in differentiation of benign and malignant liver than traditional crossed affinity immunoelectrophoresis autoradiography method.
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / chemistry. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469181.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


42. Chen C, Wang G, Zhang ZM, Xu W, Li Q, Hu Q, Wang D, Li ZP, Yang ZX, Suo JY, Zheng JJ, Wang HZ: [The expression of Tec and the level of its phosphorylation in primary hepatic carcinomas]. Zhonghua Gan Zang Bing Za Zhi; 2007 Dec;15(12):910-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of Tec and the level of its phosphorylation in primary hepatic carcinomas].
  • OBJECTIVES: To detect the expressions of Tec tyrosine kinase in hepatocellular carcinoma and the levels of phosphorylation of tyrosine kinase in liver cancer tissues, paracancerous tissues and normal liver tissues and to find the significance of their differences.
  • METHODS: 200 specimens of tissues, including liver cancer tissues, surrounding liver tissues not more than 1.5 cm from the cancers, and normal liver tissues were investigated for Tec protein expression and Tec phosphorylation by tissue microarrays and immunohistochemistry (SP method).
  • RESULTS: The positive immunohistochemical stainings of Tec in cancerous tissues and non-cancerous tissues showed no obvious differences, nevertheless, the immunostaining levels in liver cancer tissues were much higher than in non-cancerous tissues and they correlated with the grading of tumors (P < 0.05).
  • The phosphorylation of Tec was significantly expressed in liver cancer tissues (73%) in comparison with other tissues (42%, 10% both P < 0.05), but it did not correlate with any clinicopathological characteristics.
  • CONCLUSION: Overexpression of Tec is associated with the tumorigenesis and development of liver cancer; inhibiting Tec or degrading Tec phosphorylation directly might affect the progression of liver cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neoplasm Proteins / metabolism. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Phosphorylation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18171525.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.1.- / Tec protein-tyrosine kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


43. Brouwer J, Senft A, de Bree R, Comans EF, Golding RP, Castelijns JA, Hoekstra OS, Leemans CR: Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol; 2006 Mar;42(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The detection of distant metastases and second primary tumours at the time of initial evaluation changes the prognosis and influences the selection of treatment modality in patients with HNSCC.
  • In this observational cohort study we prospectively compared the yield of whole body (18)FDG-PET and chest CT to detect distant metastases and synchronous primary tumours.
  • Four patients were diagnosed with distant metastases or second primary tumours: CT as well as (18)FDG-PET identified one patient with lung metastases and another with primary lung cancer.
  • In addition, (18)FDG-PET detected second primary tumours in two patients (hepatocellular carcinoma and abdominal adenocarcinoma).
  • However increased uptake sites at (18)FDG-PET in lung, liver and pelvis in five patients were not confirmed by other imaging modalities.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Fluorodeoxyglucose F18. Head and Neck Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / radionuclide imaging. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266820.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Casaril A, Abu Hilal M, Harb A, Campagnaro T, Mansueto G, Nicoli N: The safety of radiofrequency thermal ablation in the treatment of liver malignancies. Eur J Surg Oncol; 2008 Jun;34(6):668-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The safety of radiofrequency thermal ablation in the treatment of liver malignancies.
  • INTRODUCTION: Radiofrequency ablation (RFA) has become widely accepted as an important adjunct, and sometimes a viable alternative, to liver surgery.
  • PATIENTS AND METHODS: This is a review of 130 consecutive patients who were treated for primary (n = 92) and metastatic (n = 38) liver tumours.
  • Patient's liver function and general health as well as tumour size and position must be considered.
  • Intraoperative or video laparoscopic RFA is useful for superficial tumours in order to avoid damage to viscera surrounding the liver surface.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation / adverse effects. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Safety. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681717.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Gao WB, Han JD, Du M: [Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Nov;25(11):980-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma].
  • OBJECTIVE: To evaluate the clinical efficacy and side effects of Shelian capsule (SLC) as adjuvant of embolismic chemotherapy on primary hepatic carcinoma.
  • METHODS: One hundred and twenty patients with hepatic carcinoma were conducted arterial embolismic chemotherapy with FAM program for two therapeutic cycles.
  • The tumor size, Karnofsky score, clinical symptoms, alpha fetoprotein (AFP), NK cell, T cell-subgroup and adverse effect before and after treatment between the two groups were compared respectively.
  • The ratio of CD4/CD8 and NK cell activity was significantly different between the two groups (P<0.05).

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16355611.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Capsules; 0 / Drugs, Chinese Herbal; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Imataki O, Makimoto A, Kojima R, Sakiyama M, Hosono A, Takaue Y: Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases. Int J Clin Oncol; 2006 Apr;11(2):156-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases.
  • Adrenocortical carcinoma is a rare malignancy in adolescents and young adults.
  • The prognosis of unresectable/metastatic adrenocortical carcinoma remains very poor because the rarity of the tumor has made it difficult to establish treatment guidelines, and diagnosis and the resultant treatment can be greatly delayed.
  • We treated a 24-year-old woman who was diagnosed with adrenocortical carcinoma of the right adrenal gland which extended to the inferior vena cava.
  • Although she underwent surgical resection of the extensive tumor as the primary treatment, the disease recurred in the lung and liver as multiple metastases shortly after surgery.
  • She received intensive multimodality therapy, including chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP regimen), embolization of the feeding arteries, and proton irradiation for the liver mass.
  • Finally, she underwent reduced-intensity allogeneic hematopoietic stem cell transplantation from an HLA 1-locus-mismatched sibling donor.
  • Although this experience is limited, we suggest that TIP chemotherapy was effective for adrenocortical carcinoma, and a graft-versus-tumor effect after reduced-intensity stem cell transplantation may have contributed to the prolonged survival.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Liver Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Graft vs Host Disease. Humans


47. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2008 Jan;19(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.
  • Primary end point was overall survival (OS).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938425.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; 80061L1WGD / Cimetidine; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


48. Duan YW, Huang Y, Cai LQ, Duan Q, Zhu YS: Inhibition of tumor growth and tumor metastasis by a Chinese herbal formula--ZYD88, in an animal model with metastatic Lewis lung carcinoma. Oncol Rep; 2007 Jun;17(6):1391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of tumor growth and tumor metastasis by a Chinese herbal formula--ZYD88, in an animal model with metastatic Lewis lung carcinoma.
  • In the present study, we determined the effectiveness of ZYD88, a Chinese herbal formula, in the inhibition of tumor growth and distant tumor metastases to the lung and liver in an animal model with metastatic Lewis lung carcinoma (LLC).
  • Treatment with ZYD88 in adult C57BL/6 mice with metastatic LLC produced dose-dependent deceases in primary tumor weight, the mitotic tumor cell number, microvessel density, distant tumor metastases and red blood cell immune complexes, while it significantly increased tumor necrosis, thymus cortical thickness, the thymus medullar reticular epithelial cell (REC) number, and the activity of red blood cell C3b receptors.
  • Although cyclophosphamide inhibited tumor growth, it had no significant effects on distant tumor metastases, thymus cortical thickness, the thymus medullar REC number, red blood cell C3b receptor activity and red blood cell immune complexes.
  • [MeSH-major] Carcinoma, Lewis Lung / prevention & control. Carcinoma, Lewis Lung / secondary. Drugs, Chinese Herbal / therapeutic use. Liver Neoplasms / prevention & control. Liver Neoplasms / secondary. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Animals. Capillaries / drug effects. Cell Proliferation / drug effects. Disease Models, Animal. Immunity / drug effects. Mice. Mice, Inbred C57BL. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487396.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / ZYD88 herbal formula
  •  go-up   go-down


49. Nanashima A, Shibata K, Nakayama T, Tobinaga S, Araki M, Kunizaki M, Takeshita H, Hidaka S, Sawai T, Nagayasu T, Yasutake T: Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma. Ann Surg Oncol; 2009 Aug;16(8):2130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma.
  • BACKGROUND: Microvessel count (MVC) has been correlated with patient prognosis in hepatocellular carcinoma.
  • We investigated whether MVC assessed by staining with CD34 antibody was associated with disease-free and overall survival in patients with metastatic liver cancer (MLC).
  • By means of the modern Japanese classification of liver metastasis, poorer survival was associated with higher score, poorly differentiated adenocarcinoma, higher preoperative carcinoembryonic antigen (CEA) level, fibrous pseudocapsular formation, and smaller surgical margin.
  • Shorter disease-free survival was associated with higher score when the Japanese classification of liver metastasis was used, multiple or bilobar tumor, regional lymph node metastasis in primary colon carcinoma, preoperative CEA level, fibrous pseudocapsular formation, and smaller surgical margin (<5 mm).
  • [MeSH-major] Adenocarcinoma / blood supply. Colorectal Neoplasms / blood supply. Liver Neoplasms / blood supply. Microvessels / pathology. Neoplasm Recurrence, Local / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Female. Follow-Up Studies. Hepatectomy. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Microcirculation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome. Young Adult


50. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, von Kalle C, Schemmer P: Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer; 2008;8:349
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
  • BACKGROUND: Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list.
  • The oral multikinase inhibitor sorafenib significantly increases overall survival and time-to-progression in patients with advanced hepatocellular cancer.
  • A total of 208 patients with histologically confirmed hepatocellular carcinoma or HCC diagnosed according to EASL criteria will be enrolled.
  • Evaluation of time-to-progression as primary endpoint (TTP) will be performed at 120 events.
  • DISCUSSION: As TACE is the most widely used primary treatment of HCC before LTx and sorafenib is the only proven effective systemic treatment for advanced HCC there is a strong rational to combine both treatment modalities.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Double-Blind Method. Female. Humans. Liver Transplantation. Male. Niacinamide / analogs & derivatives. Phenylurea Compounds. Research Design

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2004 Nov;40(16):2439-44 [15519517.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Liver Transpl. 2005 Jul;11(7):767-75 [15973710.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S105-8 [16286885.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1505-14 [16315294.001]
  • [Cites] Liver Transpl. 2006 Apr;12(4):665-73 [16482577.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Liver Transpl. 2003 Jun;9(6):557-63 [12783395.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Liver Transpl. 2004 Mar;10(3):449-55 [15004776.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] N Engl J Med. 1995 May 11;332(19):1256-61 [7708069.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3 [9409568.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):788-94 [15760403.001]
  • (PMID = 19036146.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN24081794
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2630329
  •  go-up   go-down


51. Abbasi A, Butt N, Bhutto AR, Gulzar K, Munir SM: Hepatocellular carcinoma: a clinicopathological study. J Coll Physicians Surg Pak; 2010 Aug;20(8):510-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: a clinicopathological study.
  • OBJECTIVE: To describe the clinico-pathological and radiological profile of hepatocellular carcinoma.
  • METHODOLOGY: All consecutive patients suspected of having hepatocellular carcinoma (HCC), were admitted and included in this study.
  • Patients with primary carcinoma elsewhere in the body, metastatic in the liver, fibrolamellar carcinoma and benign tumours were excluded from the study.
  • RESULTS: There were 82 patients with hepatocellular carcinoma including 58 males and 24 females, with male to female ratio of 2.8:1.
  • Tumour size was larger than 50% of liver size in 42 (51.2%) with portal vein thrombosis in 10 (12.19%).
  • According to Okuda staging system 18 patients had stage 1, 50 had stage 2 and 14 had stage 3 hepatocellular carcinoma.
  • CONCLUSION: The mean age of presentation of hepatocellular carcinoma was younger as compared to western countries with potentially large non-resectable lesions.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20688014.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


52. Itin P, Tomaschett S: [Cutaneous metastases from malignancies which do not originate from the skin. An epidemiological study]. Internist (Berl); 2009 Feb;50(2):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 19 had breast cancer (51%), 8 sarcomas (21%), 2 leukemia (5%), 2 colorectal cancer, and one each ovary carcinoma, bronchial cancer, prostate cancer, malignant histiocytoma and Non-Hodgkin lymphoma (3%).
  • In 24 cases the primary malignancy was known (65%).
  • In 35% cutaneous metastases were diagnosed at the same time as the primary tumour.
  • Primary malignancies were diagnosed in 54% within the age range of 50-70 years, and 65% of cutaneous metastases were diagnosed within the age range of 50-80 years.
  • In 49% other known metastases were present (5% locoregional, 38% lymph nodes, 3% brain, 3% lung, 3% liver).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Middle Aged. Risk Assessment. Switzerland / epidemiology


53. Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB: Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol; 2010 May;49(4):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / drug therapy. Indoles / therapeutic use. Kidney Neoplasms / complications. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy / methods. Nephrectomy. Pyrroles / therapeutic use. Vena Cava, Inferior. Venous Thrombosis / etiology
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Disease Progression. Fatal Outcome. Humans. Liver Neoplasms / secondary. Middle Aged. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20105087.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


54. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R: Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol; 2008 Aug;44(8):743-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The oral region is an uncommon site for metastatic tumour cell colonization and is usually evidence of a wide spread disease.
  • The major primary sites presenting oral metastases were the lung, kidney, liver, and prostate for men, breast, female genital organs (FGO), kidney, and colo-rectum for women.
  • The primary site differs according to oral site colonization, in men the lung was the most common primary site affecting both the jawbones and oral mucosa (22% and 31.3%, respectively) followed by the prostate gland in the jawbones (11%) and kidney in the oral soft tissues (14%).
  • In women, the breast was the most common primary tumour affecting the jawbones and soft tissues (41% and 24.3%, respectively), followed by the adrenal and female genital organs (FGO) in the jawbones (7.7%) and FGO in the soft tissues (14.8%).
  • Early manifestation of the gingival metastases resembled a hyperplastic or reactive lesion, such as pyogenic granuloma, peripheral giant cell granuloma, or fibrous epulis.
  • [MeSH-major] Carcinoma / secondary. Jaw Neoplasms / secondary. Mouth Neoplasms / secondary
  • [MeSH-minor] Adult. Case-Control Studies. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Sex Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061527.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 150
  •  go-up   go-down


55. Kang CM, Choi GH, Kim DH, Choi SB, Kim KS, Choi JS, Lee WJ: Revisiting the role of nonanatomic resection of small (&lt; or = 4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function. J Surg Res; 2010 May 1;160(1):81-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the role of nonanatomic resection of small (< or = 4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function.
  • BACKGROUND: Anatomic resection of the liver in patients with hepatocellular carcinoma (HCC) is generally recommended.
  • We evaluated the oncologic outcomes of nonanatomic resection performed as a primary treatment for small (<or=4 cm) and single HCC in patients with well-preserved liver function (Child-Pugh class A).
  • Among them, 167 patients with single and small (<or=4 cm) HCC and well-preserved liver function (Child-Pugh class A) were selected.
  • CONCLUSION: Our study showed that nonanatomic resection has no adverse effects on the oncologic outcomes of single and small (<or=4 cm) HCC in patients with well-preserved liver function (Child-Pugh class A).
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Korea / epidemiology. Liver / pathology. Liver Function Tests. Male. Middle Aged. Platelet Count. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19577249.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Liang YM, Li XH, Lü YL, Zhong M: [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. Zhonghua Yi Xue Za Zhi; 2005 Jan 12;85(2):96-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors].
  • OBJECTIVE: To investigate the morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors, and to conclude the diagnostic and differential diagnostic criteria for these morphologically similar tumors.
  • METHODS: Forty-six specimens of hepatic spindle cell tumors.
  • 20 primary tumors (43.4%), including 3 cases of sarcomatoid carcinoma (6.5%), 11 of angiosarcoma (23.9%), 2 of epithelioid hemangioendothelioma (5%), 1 of spindle cell carcinoid (2.2%), and 3 of undifferentiated sarcoma (6.5%).
  • and 26 metastatic malignant tumors (56.5%), including 20 cases of gastrointestinal stromal tumors (GIST, 43.4%), 3 of leiomyosarcoma (6.5%), 2 of malignant peripheral never sheath tumor (4.3%), and 1 of meningeal hemangiopericytoma (2.2%), resected during operation or collected during imaging-mediated liver puncture underwent hematoxylin-eosin staining, SP staining, and EnVision immunohistochemical staining.
  • RESULTS: Either primary or metastatic tumors showed extensive overlapping in histopathologic appearance, and hemangiopericytoma-like structure was the predominant pattern, which could be seen in nearly every kind of hepatic spindle cell tumors.
  • Most stromal tumor cases were CD117 positive, and existed the condition that the primary tumor was positive and the metastatic tumor was negative or vice versa or one part of specimen was positive but other part was negative.
  • Sarcomatoid carcinoma was positive for CK and vimentin.
  • Spindle cell carcinoid was positive for CK and neuroendocrine markers, such as synaptophysin and chromogranin A.
  • CONCLUSION: Primary angiosarcoma is the most common form of primary spindle cell tumor in liver, and metastatic GIST is predominant in hepatic metastatic spindle cell tumors.
  • [MeSH-major] Carcinoma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Biomarkers, Tumor. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774214.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Yong CC, Chen YS, Wang SH, Lin CC, Liu PP, Liu YW, Yang CH, Hung KC, Chiang YC, Lin TS, Cheng YF, Huang TL, Jawan B, Eng HL, Chen CL, Wang CC: Deceased-donor liver transplantation: 10 years' experience at Change Gung Memorial Hospital-Kaohsiung Medical Center. Chang Gung Med J; 2005 Mar;28(3):133-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deceased-donor liver transplantation: 10 years' experience at Change Gung Memorial Hospital-Kaohsiung Medical Center.
  • BACKGROUND: The purpose of this study was to summarize the outcomes we achieved using deceased-donor liver transplantation (DDLT) in the past 10 years at Chang Gung Memorial Hospital-Kaohsiung Medical Center (CGMH-KMC).
  • RESULTS: Indications for transplantation were biliary atresia (16), post-hepatitis B/C viral cirrhosis with or without hepatocellular carcinoma (21), Wilson's disease (8), primary biliary cirrhosis (3), and miscellaneous (5).
  • Two retransplants were carried out for secondary biliary cirrhosis using primary live-donor liver transplantation (LDLT).
  • Ten patients received grafts from 6 split-liver transplantations.
  • CONCLUSIONS: Deceased-donor liver transplantation is well established as the treatment of choice for acute and chronic liver failure in Taiwan.
  • [MeSH-major] Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Cadaver. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Postoperative Complications / etiology. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945319.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


58. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer.
  • Although the lung, liver, or bones are the most common location for distant metastases in breast cancer patients, metastases to the intestinal tract are very rarely recognized in the clinic.
  • We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a through review of English language medical literature.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


59. Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, Schirrmacher P, Klöppel G, Altevogt P, Schäfer H, Sebens Müerköster S: Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep; 2010 Oct;24(4):909-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma.
  • Recently, we identified L1CAM expression in pancreatic ductal adenocarcinoma (PDAC) cells accounting for chemoresistance and increased cell migration.
  • L1CAM expression was determined by immunohistochemistry in tissues of 123 patients including tissues of 110 primary PDACs, 15 lymph node metastases and 14 liver metastases.
  • The immunohistochemical analyses revealed L1CAM expression in 92.7% of primary PDACs, 80% of lymph node metastases and 100% of liver metastases.
  • Furthermore, its broad expression in primary tumors as well as in metastases of PDAC patients provide a rationale to further explore the value of L1CAM as a therapeutic target in the treatment of this highly malignant tumor.
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Neural Cell Adhesion Molecule L1 / biosynthesis. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811670.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


60. Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS: Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol; 2010 Jul;21(7):1024-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization.
  • PURPOSE: To determine the effects of primary chemoembolization on the health-related quality of life (HRQOL) of patients with hepatocellular carcinoma (HCC).
  • CONCLUSIONS: Patients with HCC are likely to perceive improved mental health during the first 4 months of primary treatment with chemoembolization.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / statistics & numerical data. Liver Neoplasms / epidemiology. Liver Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Longitudinal Studies. Male. Maryland / epidemiology. Middle Aged. Prevalence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20621715.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Yan K, Chen MH, Dai Y, Shen L, Jiang XL: [Results of enhanced ultrasonography in assessing hepatoma treated with radiofrequency ablation]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of enhanced ultrasonography in assessing hepatoma treated with radiofrequency ablation].
  • METHODS: Eighteen patients with 17 primary hepatocellular carcinoma and 1 hepatic metastasis were studied.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Catheter Ablation. Liver Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771798.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


62. Méndez Romero A, Wunderink W, van Os RM, Nowak PJ, Heijmen BJ, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC: Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors.
  • PURPOSE: Stereotactic body radiation therapy (SBRT) provides a high local control rate for primary and metastatic liver tumors.
  • This is the first report of quality of life associated with liver SBRT.
  • METHODS AND MATERIALS: From October 2002 to March 2007, a total of 28 patients not suitable for other local treatments and with Karnofsky performance status of at least 80% were entered in a Phase I-II study of SBRT for liver tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Quality of Life. Stereotaxic Techniques
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Prospective Studies. Surveys and Questionnaires / standards

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996394.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Choi HN, Kim KR, Lee JH, Park HS, Jang KY, Chung MJ, Hwang SE, Yu HC, Moon WS: Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol Rep; 2009 Jan;21(1):57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
  • Serum response factor (SRF) is a transcription factor that controls cell growth, differentiation, and tumor progression as well as muscle development and function.
  • Reduced expression of cell adhesion molecules has been reported to be associated with tumor metastasis.
  • The aim of this study was to evaluate the expression and a role of SRF in liver metastasis of primary colorectal carcinomas.
  • We examined the expression of SRF, E-cadherin, and beta-catenin by the use of immunochemical staining in 43 cases as a set of primary colorectal carcinomas and liver metastases.
  • We also examined the role of SRF in colorectal carcinoma by overexpression of SRF in a colon cancer cell line.
  • In metastatic carcinoma surgical samples, there was a marked increased expression of SRF as compared to expression in primary colorectal carcinoma surgical samples (P<0.05).
  • E-cadherin expression was significantly decreased in metastatic liver carcinoma samples as compared to primary colorectal carcinoma samples (P<0.001).
  • Frequent nuclear translocation of beta-catenin protein in primary and metastatic carcinoma cells was observed.
  • Overexpression of SRF in colorectal carcinoma cells enhanced cell motility and invasiveness.
  • These results indicate that overexpression of SRF in colorectal carcinoma cells is associated with modulation of E-cadherin/beta-catenin expression and may play an important role in colorectal cancer metastasis.
  • [MeSH-major] Cadherins / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Serum Response Factor / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Middle Aged. Transfection

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082443.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Serum Response Factor; 0 / beta Catenin
  •  go-up   go-down


64. Sapisochin G, Bilbao I, Balsells J, Dopazo C, Caralt M, Lázaro JL, Castells L, Allende H, Charco R: Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg; 2010 Sep;34(9):2146-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series.
  • BACKGROUND: The aim of this study was to ascertain the outcome of liver transplantation (LT) due to hepatocellular carcinoma (HCC) in patients who had undergone previous liver resection (LR) for HCC.
  • METHODS: A case-control study (1:2) was designed to compare patients who underwent LT due to HCC recurrence with a previous LR for HCC (study group) with those who underwent LT for primary HCC but without previous LR (control group).
  • RESULTS: From January 1990 to December 2007, a total of 303 cirrhotic patients with primary HCC were evaluated for surgery.
  • Primary LT was performed in 191 and LR in 100.
  • CONCLUSIONS: Liver transplantation can be safely performed after a previous LR for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Liver Cirrhosis / complications. Liver Function Tests. Male. Middle Aged. Prognosis. Reoperation. Treatment Outcome. Ultrasonography


65. Turato C, Ruvoletto MG, Biasiolo A, Quarta S, Tono N, Bernardinello E, Beneduce L, Fassina G, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P: Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Dig Liver Dis; 2009 Mar;41(3):212-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease.
  • BACKGROUND: The serpin squamous cell carcinoma antigen (SCCA, SERPINB3) has been found over-expressed in primary liver cancer and at lower extent in cirrhosis and chronic hepatitis.
  • AIM: To explore SCCA-1 polymorphism in patients with HCV infection as single etiologic factor and different extent of liver disease.
  • CONCLUSIONS: The newly identified SCCA-PD variant was more frequently found in liver cirrhosis, suggesting that patients carrying this polymorphism are more prone to develop progressive liver fibrosis.
  • [MeSH-major] Antigens, Neoplasm / genetics. Liver Diseases / genetics. Polymorphism, Restriction Fragment Length. Serpins / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Chronic Disease. Female. Humans. Immunoglobulin M / blood. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657489.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin M; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


66. Rivera L, Giap H, Miller W, Fisher J, Hillebrand DJ, Marsh C, Schaffer RL: Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol; 2006 Sep 21;12(35):5729-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report.
  • Hepatocellular carcinoma (HCC) recurs with a reported frequency of 12%-18% after liver transplantation.
  • Approximately one-third of recurrences develop in the transplanted liver and are therefore amenable to local therapy.
  • Yttrium-90 microspheres have been used as a treatment modality both for primary HCC and for pre-transplant management of HCC with promising results.
  • Twenty-two months after liver transplantation for hepatitis C cirrhosis complicated by HCC, a 42-year old man developed recurrence of HCC in his transplant allograft.
  • Multifocal recurrence in the remaining liver allograft was treated with hepatic intra-arterial infusion of yttrium-90 microspheres (SIR-Spheres, Sirtex Medical Inc., Lake Forest, IL, USA).
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Hepatitis C. Humans. Infusions, Intra-Arterial. Liver Transplantation. Male. Microspheres. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1747-52 [11920537.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] Transplantation. 2002 Dec 27;74(12):1746-51 [12499891.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S107-10 [14762849.001]
  • [Cites] Psychooncology. 2004 Feb;13(2):73-9 [14872525.001]
  • [Cites] Liver Transpl. 2005 Sep;11(9):1127-31 [16123954.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):195-203 [15713920.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):205-13 [15713921.001]
  • [Cites] Arch Surg. 2005 Apr;140(4):353-8 [15837885.001]
  • [Cites] Liver Transpl. 2004 Apr;10(4):534-40 [15048797.001]
  • (PMID = 17007031.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ PMC4088179
  •  go-up   go-down


67. Mohan V, Jones RC, Drake AJ 3rd, Daly PL, Shakir KM: Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen. Thyroid; 2005 Feb;15(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen.
  • Papillary thyroid carcinoma (PTC) commonly metastasizes to cervical lymph nodes.
  • Well-differentiated thyroid carcinoma very rarely presents with metastases to the spleen.
  • This is the case of a 25-year-old man with a history of PTC (1.4 cm primary; no capsular invasion and negative lymph node metastases).
  • Contrast CT of the abdomen showed multiple low-attenuated heterogeneously enhancing splenic masses, normal liver and no intra-abdominal lymphadenopathy.
  • Despite the serum thyroglobulin of only 9.4 ng/mL, the finding of I(131) accumulation within solid splenic masses led to a preoperative diagnosis of thyroid carcinoma metastases.
  • Histopathologic analysis showed large littoral cell angiomas (LCA).
  • To our knowledge, this is the first case that describes multiple angiomas mimicking metastatic thyroid carcinoma to the spleen.
  • This is the first report of an association between LCA and thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / secondary. Hemangioma / pathology. Splenic Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. False Positive Reactions. Female. Humans. Iodine Radioisotopes. Tomography, X-Ray Computed. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Angioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753678.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


68. Vivekanandan P, Torbenson M: Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol; 2008 Jun;21(6):670-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas.
  • Fibrolamellar carcinomas have a unique predilection for younger individuals and arise in livers without recognizable liver disease.
  • In contrast to typical hepatocellular carcinomas, fibrolamellar carcinomas show few chromosomal changes and lack mutation in key genes such as TP53 and CTNNB1.
  • Nine fibrolamellar carcinomas were studied including primary tumors (N=5) and metastatic deposits (N=4) along with control groups of typical hepatocellular carcinoma arising in livers with (N=21) and without cirrhosis (N=10).
  • However, fibrolamellar carcinomas showed significantly less methylation than hepatocellular carcinomas that arose in the background of viral cirrhosis.
  • In conclusion, fibrolamellar carcinoma shows low levels of methylation.
  • In contrast, higher levels of promoter methylation are associated with hepatocellular carcinomas that arise in the setting of viral induced cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. DNA Methylation. Epigenesis, Genetic. Liver Neoplasms / genetics. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Genes, Tumor Suppressor. Hepatitis C, Chronic. Humans. Liver Cirrhosis / virology. Male. Promoter Regions, Genetic


69. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF Jr, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA, Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare: A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1035-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Women with ovarian, fallopian tube, or primary peritoneal carcinoma and documented recurrent disease were eligible for the study.
  • Although 43% were Eastern Cooperative Oncology Group 0, 50% had liver metastases.
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343179.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


70. Skalický T, Treska V, Spidlen V, Vodicka V, Sutnar A, Liska V, Klecka J, Simánek V, Safránek J, Fichtl J, Polák M: [Surgical treatment of liver and pulmonary metastases of colorectal carcinoma]. Rozhl Chir; 2010 Apr;89(4):253-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of liver and pulmonary metastases of colorectal carcinoma].
  • THE AIM: The aim of the work was to evaluate the set of 10 patients, who were operated on hepatic and pulmonary metastases of colorectal carcinoma at the Surgical Clinic of Medical Faculty of Charles University and Faculty Hospital in Plzeń in years from 2005 till 2009.
  • THE SET OF THE PATIENTS: In years from 2005 till 12/2009 we operated 10 patients during whose affection there occurred hepatic and pulmonary metastases of colorectal carcinoma and these were solved surgically.
  • In 10% it was hepatic resection in the first period after the operation of primary carcinoma, it was the first performance on the hepatic parenchyma in 90%.
  • In 4 cases primary carcinoma was in the rectum and in 6 cases in the large intestine.
  • Resection on liver parenchyma was the most often performance and metastasectomy with the help of laser on the pulmonary parenchyma.
  • Rectal carcinoma spread into lungs in 50%.
  • An average time of a 5-year survival in the patients after resection of hepatic and pulmonary metastases of colorectal carcinoma was 26%.
  • THE CONCLUSION: Hepatic and pulmonary resection in the selected patients with generalized colorectal carcinoma extends the period of a survival and does not worsen the quality of the life.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586164.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


71. Mourad W, Khalaf H, Tulbah A, Al Omari M, Al Mana H, Neimatallah M: Clinicopathologic features of hepatic neoplasms in explanted livers: a single institution experience. Ann Saudi Med; 2007 Nov-Dec;27(6):437-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatic neoplasms can be the primary indication for hepatic transplantation.
  • RESULTS: In 98 liver transplants, 15 neoplasms (15.3%) were identified.
  • The primary etiology of hepatic disease was hepatitis C virus in 12 cases, hepatitis B virus in 1 case, cryptigenic cirrhosis in 1 case and congenital hepatic fibrosis in 1 case.
  • The tumors included hepatocellular carcinoma (HCC) in 13 cases, 1 case of choloangiocarcinoma and 1 case of combined HCC and hepatoblastoma.
  • [MeSH-major] Liver Neoplasms / etiology. Liver Neoplasms / pathology. Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. CA-19-9 Antigen / blood. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / pathology. Child. Child, Preschool. Cholangiocarcinoma / etiology. Cholangiocarcinoma / pathology. Female. Follow-Up Studies. Gene Expression. Hepatitis B / complications. Hepatitis C / complications. Hepatoblastoma / etiology. Hepatoblastoma / pathology. Humans. Liver Cirrhosis / complications. Male. Middle Aged. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059117.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


72. Gressner OA, Gao C, Siluschek M, Kim P, Gressner AM: Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma. Eur J Gastroenterol Hepatol; 2009 Sep;21(9):990-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma.
  • BACKGROUND AND AIM: Next to its role as a carrier protein for vitamin D and its plasma metabolites, the primary function of vitamin D-binding protein (DBP; Gc-globulin) is to serve and to bind and neutralize extracellular monomeric actin (G-actin) released from necrotic cells, which in its long filamentous form (F-actin) triggers coagulation.
  • We, therefore, investigated the kinetics of serum concentrations of actin-free DBP during the pathogenetic sequence from liver fibrosis to hepatocellular carcinoma (HCC) to initiate a discussion on a hypothetical association of serum concentrations of actin-free DBP and, thus, altered actin clearance in the circulation, and an increased risk of thrombosis in patients with functional liver insufficiency.
  • RESULTS: Our data show that serum levels of actin-free DBP are decreased in patients with liver fibrosis (n=288) and HCC (n=102) compared with healthy controls (n=120 and n=63) and nonliver disease sick (n=312) and that the level of decrease correlates with the severity of disease as determined according to the score by the French METAVIR Cooperative Study Group staging system for hepatic fibrosis or the Edmondson-Steiner's grading system for the assessment of HCC.
  • CONCLUSION: Although further, in particular, longitudinal studies are still necessary to back up our data, the presented findings suggest that decreasing levels of the actin-scavenger DBP could potentially contribute to the thrombophilic predisposition frequently observed in patients with chronic fibrogenic liver disease and HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Cirrhosis / pathology. Liver Neoplasms / pathology. Vitamin D-Binding Protein / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / blood. Female. Germany. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322100.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vitamin D-Binding Protein
  •  go-up   go-down


73. Mangus RS, Fridell JA, Vianna RM, Milgrom ML, Chestovich P, Vandenboom C, Tector AJ: Severe hypernatremia in deceased liver donors does not impact early transplant outcome. Transplantation; 2010 Aug 27;90(4):438-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypernatremia in deceased liver donors does not impact early transplant outcome.
  • BACKGROUND: There may be an increased risk of primary nonfunction in livers procured from donors with hypernatremia.
  • METHODS: The organ procurement records for 1013 consecutive deceased liver donors between 2001 and 2008 were reviewed.
  • Outcomes included 30-day posttransplant alanine aminotransferase and total bilirubin, primary nonfunction, and 30-day and 1-year graft survival.
  • The study groups did not differ in recipient age, model for end-stage liver disease score, steatosis, and ischemia times for the peak or terminal serum sodium groups.
  • The differing levels of hypernatremia severity did not differ importantly, for peak or terminal serum sodium, in posttransplant alanine aminotransferase or total bilirubin, or the risk of intraoperative death and primary nonfunction.
  • CONCLUSIONS: Posttransplant measures of early liver function and risk of failure, up to 1-year posttransplant, did not differ significantly based on peak or terminal donor serum sodium levels.
  • These results suggest that donor serum sodium level likely has little clinical impact on posttransplant liver function.
  • [MeSH-major] Cadaver. Hypernatremia / physiopathology. Liver Failure / surgery. Liver Transplantation / physiology. Tissue Donors
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Hepatocellular / surgery. Female. Hepatitis C / surgery. Humans. Liver Neoplasms / surgery. Male. Middle Aged. Retrospective Studies. Treatment Outcome


74. Padilla GF, Garibay MA, Hummel HN, Avila R, Méndez A, Ramírez R: [Fulminant non-Hodgkin lymphoma presenting as lactic acidosis and acute liver failure: case report and literature review]. Acta Gastroenterol Latinoam; 2009 Jun;39(2):129-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fulminant non-Hodgkin lymphoma presenting as lactic acidosis and acute liver failure: case report and literature review].
  • Hepatic dysfunction caused by malignancy is uncommon and can be the result of primary hepatocellular carcinoma, liver metastasis, secondary malignancies, or a complication of chemotherapeutic agents.
  • Hematological malignancies, as leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma, typically do not result in hepatic dysfunction and rarely manifest as fulminant liver failure.
  • However, symptoms progressed and he was admitted with advanced liver failure.
  • The abdomen was tender with an enlarged liver.
  • Abdominal ultrasound showed liver and spleen enlargement.
  • CONCLUSIONS: Acute liver failure is uncommon as the presenting feature of lymphoma.
  • Establishing a diagnosis of malignancy as the cause of acute liver failure is difficult and requires a high index of suspicion.
  • Given the poor prognosis associated with late or missed diagnosis and the potential benefits of early chemotherapy, lymphoma should be considered in any patient presenting with acute liver failure without an obvious etiology and associated with lactic acidosis and hepatomegaly.
  • [MeSH-major] Acidosis, Lactic / etiology. Liver Failure, Acute / etiology. Liver Neoplasms / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male


75. Li DT, Ling CQ, Zhu DZ: [Study on the quantitative evaluation on the degree of TCM basic syndromes often encountered in patients with primary liver cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jul;27(7):602-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the quantitative evaluation on the degree of TCM basic syndromes often encountered in patients with primary liver cancer].
  • OBJECTIVE: To establish a quantitative model for evaluating the degree of the TCM basic syndromes often encountered in patients with primary liver cancer (PLC).

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717917.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


76. Wilmanns C, Steinhauer S, Grossmann J, Ruf G: Site-dependent differences in clinical, pathohistological, and molecular parameters in metastatic colon cancer. Int J Biol Sci; 2009;5(5):458-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumour stage (OA, EMT), lymphonodal stage (OA), the presence of a lymphangiosis carcinomatosa (OA), histological grade (OA, EMT), and immunoblot extraction of E-cadherin (OA, EMT) were differentially rated with zero to one or two points due to their potential contribution to each process and the resulting scores were validated in 27 colorectal cancer patients (three patients with pre-malignant adenomas, 16 with primaries and two with local recurrencies, three of which were metastatic to the peritoneum, six metastatic to the liver and two metastatic to both, the liver and the peritoneum, and five with hepatic secondaries, one of which at histology was metastatic to the peritoneum too).
  • Median OA and EMT scores, however, were 3.5 and 2 in the case of primaries without further spread, 5 and 4 in those nodal positive, 5 and 4 in the case of peritoneal implants, 6 and 2 in the case of liver metastases, and 6.5 and 3 in the case of a simultaneous hepatic and peritoneal spread, respectively.
  • These differences were significant when scores from patients with and without liver metastases (OA, p<0.002) or with peritoneal implants and isolated hepatic spread (EMT, p<0.01) were compared.
  • [MeSH-major] Carcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary. Severity of Illness Index
  • [MeSH-minor] Adenoma / pathology. Adult. Aged. Cell Transdifferentiation. Colon / pathology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):488-96 [15864483.001]
  • [Cites] Cell. 2006 Dec 1;127(5):875-7 [17129772.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1027-39 [17129786.001]
  • [Cites] Zentralbl Chir. 2007 Dec;132(6):509-14 [18098078.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6092-9 [18676831.001]
  • [Cites] Cell Cycle. 2009 Jan 15;8(2):284-98 [19177011.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] J Cell Biol. 1998 Jul 13;142(1):85-100 [9660865.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Cell. 1995 Oct 6;83(1):5-8 [7553873.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3827-38 [8508351.001]
  • [Cites] Clin Exp Metastasis. 2004;21(1):75-8 [15065605.001]
  • [Cites] Nature. 2004 Aug 26;430(7003):1034-9 [15329723.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):711-9 [15252840.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6750-6 [11118062.001]
  • [Cites] Hepatology. 2003 Aug;38(2):470-80 [12883492.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6292-8 [1834329.001]
  • (PMID = 19564929.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2702829
  • [Keywords] NOTNLM ; colon cancer / epithelial-mesenchymal transition / metastatic score / oncogenic activation
  •  go-up   go-down


77. de Meijer VE, Verhoef C, Kuiper JW, Alwayn IP, Kazemier G, Ijzermans JN: Radiofrequency ablation in patients with primary and secondary hepatic malignancies. J Gastrointest Surg; 2006 Jul-Aug;10(7):960-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation in patients with primary and secondary hepatic malignancies.
  • The aims of this study were to assess the technical effectiveness of radiofrequency (RF) ablation in patients with primary or secondary hepatic malignancies and to determine survival and complication rates.
  • [MeSH-major] Catheter Ablation. Liver Neoplasms / therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Colorectal Neoplasms / pathology. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Netherlands. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Sep;232(3):381-91 [10973388.001]
  • [Cites] Am J Surg. 2001 Dec;182(6):552-7 [11839316.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):566-71 [9563547.001]
  • [Cites] Radiology. 2004 Jan;230(1):135-41 [14631050.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):593-600 [11005558.001]
  • [Cites] Br J Surg. 2002 Oct;89(10):1206-22 [12296886.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1714-23 [15578509.001]
  • [Cites] Radiology. 2005 Jun;235(3):728-39 [15845798.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):102-7 [15213625.001]
  • [Cites] Clin Radiol. 2004 Jan;59(1):53-61 [14697375.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):791-6 [13129558.001]
  • [Cites] Dig Surg. 2004;21(4):314-20 [15365230.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):759-64 [14585410.001]
  • [Cites] Radiology. 2000 Mar;214(3):761-8 [10715043.001]
  • [Cites] Lancet. 1998 Jan 17;351(9097):214-5 [9449893.001]
  • [Cites] Eur Radiol. 2004 Dec;14(12):2261-7 [15599547.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):480-4 [12749252.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1201-9 [15690326.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):91-9 [15757806.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):155-69 [15069676.001]
  • [Cites] Surg Endosc. 2003 Jan;17(1):61-7 [12360376.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):624-30 [12174368.001]
  • [Cites] Eur Radiol. 2001;11(6):914-21 [11419162.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):174-82 [8129488.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1240-3 [14515293.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 [11090390.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1530-8 [15196537.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):450-8 [15024305.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):255-63 [11992812.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):950-5 [12905547.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):598-605 [15172933.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1059-69 [14597445.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1142-3 [9343506.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):334-8 [14991635.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):274-6 [8472130.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):52-8 [12513961.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3027-35 [12784338.001]
  • [Cites] Eur J Surg Oncol. 2004 Jun;30(5):551-5 [15135485.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Transpl Int. 1998;11 Suppl 1:S193-6 [9664977.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • (PMID = 16843866.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 52
  •  go-up   go-down


78. Amarapurkar AD, Rege JD, Joshi AS, Vaiphei K, Amarapurkar DN: Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors. Indian J Pathol Microbiol; 2006 Jul;49(3):341-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
  • Diagnosis of hepatocellular carcinoma (HCC) is not always easy on simple hematoxylin and eosin (H&E) stain.
  • The diagnostic problems arise when tumor shows pseudoglandular, pleomorphic or clear cell differentiation.
  • Total of 62 cases of liver tumors obtained from biopsies, resected or autopsy specimens were included in the study.
  • Slides having representative sections were subjected to immunohistochemistry with monoclonal antibody Hep Par 1 (Dako Corp) using avidin biotin technique with primary antibody dilution of 1:40.
  • Hep Par 1 antibody was positive in 26 (42 %) and negative in 36 (58 %) liver tumors.
  • Only one case of liver metastasis of mucin secreting adenocarcinoma showed positivity.
  • [MeSH-major] Antibodies, Monoclonal. Antibodies, Neoplasm / immunology. Biomarkers, Tumor. Carcinoma, Hepatocellular / pathology. Hepatocytes / immunology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / immunology. Antigens, Surface / immunology. Biopsy. Cell Differentiation / immunology. Diagnosis, Differential. Humans. Immunohistochemistry. Liver / metabolism. Liver / pathology. Neoplasm Metastasis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001880.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Gross ML, Berger I: [Primary metastatic renal metastatic carcinoid tumor in a young male patient: a contribution to the differential diagnosis of neuroendocrine tumors]. Pathologe; 2007 Jul;28(4):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary metastatic renal metastatic carcinoid tumor in a young male patient: a contribution to the differential diagnosis of neuroendocrine tumors].
  • Primary renal carcinoid tumors originating in normal kidney are extremely rare.
  • We report a case of primary renal carcinoid tumor with an aggressive clinical course and multiple metastases in the paraaortal lymph nodes and the liver as well as a pulmonary metastasis, in a 30-year-old patient.
  • A CT scan of the abdomen revealed a large mass in the right kidney and multiple tumor suspect areas in the liver and paraaortal lymph nodes.
  • [MeSH-minor] Adult. Carcinoma, Neuroendocrine / pathology. Chromosome Mapping. DNA, Neoplasm / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Neoplasm Metastasis. Nucleic Acid Hybridization / methods. Tomography, X-Ray Computed


80. Giorgio A, Tarantino L, de Stefano G, Coppola C, Ferraioli G: Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol; 2005 Jan;184(1):207-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center.
  • OBJECTIVE: Our objective was to report the complications that occurred in a large series of patients with primary or metastatic liver tumors treated with percutaneous saline-enhanced radiofrequency ablation under sonographic guidance at a single center during 3 years of experience.
  • SUBJECTS AND METHODS: Between September 2000 and October 2003, 336 consecutive patients (221 men and 115 women; age range, 44-78 years; mean, 67 years) with 407 malignant liver tumors were treated at our institution using radiofrequency ablation.
  • Of these patients, 287 had hepatocellular carcinoma from cirrhosis, 47 had liver metastases (38 from colon, six from breast, two from lung, and one from cutaneous melanoma), and two had primary cholangiocarcinoma.
  • One patient died because of worsening liver decompensation.
  • In one patient (0.3%), liver abscess and sepsis developed and were successfully treated with percutaneous sonography-guided needle (18-gauge) aspiration and IV antibiotics.
  • CONCLUSION: Radiofrequency ablation of liver tumors can be considered safe.
  • Life-threatening acute liver failure can be considered a rare possible complication.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Postoperative Complications / epidemiology. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Sodium Chloride / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615976.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


81. Lau WY, Lai EC, Leung TW, Yu SC: Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg; 2008 Jan;247(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
  • OBJECTIVE: In this prospective randomized trial, we attempted to find out if 1 dose of postoperative adjuvant intra-arterial iodine-131-labeled lipiodol could reduce the rate of local recurrence, and increase disease-free and overall survival for patients with hepatocellular carcinoma (HCC).
  • We compared rates of recurrence, and long-term disease-free and overall survival (the primary endpoints) between the 2 groups by intention-to-treat.
  • CONCLUSIONS: In patients with HCC, adjuvant intra-arterial I-lipiodol after curative liver resection provided survival benefit on the disease-free survival and overall survival, although the difference became statistically insignificant at 8 years after randomization.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Carcinoma, Hepatocellular / surgery. Iodine Radioisotopes / therapeutic use. Iodized Oil / therapeutic use
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Injections, Intra-Arterial. Liver Neoplasms. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies. Radiotherapy, Adjuvant. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156922.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 8001-40-9 / Iodized Oil
  •  go-up   go-down


82. Hwang JP, Hassan MM: Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer; 2009;9:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation.
  • Timely hepatitis screening and interventions by primary care physicians may be the most logical solution to reduce the burden of hepatitis-associated HCC among Asian Americans.
  • [MeSH-major] Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / mortality. Hepatitis / complications. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Asian Americans. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival. alpha-Fetoproteins / metabolism


83. Arista-Nasr J, Fernández-Amador JA, Martínez-Benítez B, de Anda-González J, Bornstein-Quevedo L: Neuroendocrine metastatic tumors of the liver resembling hepatocellular carcinoma. Ann Hepatol; 2010 Apr-Jun;9(2):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine metastatic tumors of the liver resembling hepatocellular carcinoma.
  • Certain neuroendocrine tumors (NET) metastasized to the liver can resemble hepatocellular carcinoma (HCC) in cytological needle biopsy.
  • From a total of 285 needle biopsies with primary or metastasized hepatic neoplasms, seven cases were selected originally diagnosed as HCC or HCC vs. NET metastasized to the liver.
  • Fourteen needle biopsies of hepatocellular carcinomas were also studied for comparative purposes.
  • In all of these neoplasms the diagnosis of endocrine tumor was confirmed by immunohistochemical studies and the following information was recorded: age, sex, radiological alterations, primary site of the NET, and follow-up.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / secondary. Neuroendocrine Tumors / secondary
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mexico. Middle Aged. Predictive Value of Tests. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526014.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


84. Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, Prabhakaran PS, Benson AB: A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol; 2005 Jul-Sep;26(3):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.
  • The primary objective of this study was to determine the response rates of a combination of gemcitabine and cisplatin in unresectable hepatocellular carcinoma (HCC) in Indian patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512457.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


85. De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, Wolfgang CL, Herman JM, Edil BH, Choti MA, Schulick RD, Nagorney DM, Pawlik TM: Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg; 2010 Jul;252(1):142-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis.
  • OBJECTIVES: To analyze the perioperative and long-term outcomes of patients undergoing liver-directed therapy after pancreaticoduodenectomy in a large dual-center cohort of patients.
  • BACKGROUND: Although aggressive liver-directed therapy may be beneficial, liver-directed therapy may be associated with a high risk of complications after pancreaticoduodenectomy.
  • METHODS: Of 5025 patients who underwent pancreaticoduodenectomy at the Johns Hopkins Hospital and the Mayo Clinic between 1970 and 2008, 126 (2.5%), patients were identified who were also treated with either simultaneous or staged liver-directed therapy.
  • Data on demographics, primary tumor, and hepatic metastasis characteristics, as well as details of the liver-directed therapy were collected and analyzed.
  • RESULTS: Primary tumor histology included neuroendocrine carcinoma (34.9%), pancreatic ductal adenocarcinoma (33.4%), distal cholangiocarcinoma (8.7%), ampullary carcinoma (7.1%), duodenal carcinoma (4.0%), or other (11.9%).
  • Liver-directed therapies included hepatic resection alone (45.2%), hepatic resection plus ablation (11.1%), ablation alone (7.9%), transarterial chemoembolization (9.5%), and whole-liver irradiation (22.2%).
  • The overall morbidity following liver-directed therapy was 34.1% and overall mortality was 2.4%.
  • Patients undergoing staged liver-directed therapy (14.5%) versus simultaneous pancreaticoduodenectomy plus liver-directed therapy (7.0%) were more likely to develop a liver abscess (P < 0.05).
  • CONCLUSIONS: Pancreaticoduodenectomy plus liver-directed therapy is associated with considerable morbidity.
  • The incidence of hepatic abscess is increased in patients undergoing staged pancreaticoduodenectomy followed by liver-directed therapy.
  • [MeSH-major] Catheter Ablation. Chemoembolization, Therapeutic. Hepatectomy. Liver / radiation effects. Liver / surgery. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Pancreaticoduodenectomy
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma / pathology. Carcinoma, Ductal / pathology. Carcinoma, Neuroendocrine / pathology. Cholangiocarcinoma / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531007.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


86. Gómez Senent S, Gómez Raposo C, Manceñido Marcos N, Martín Chavarri S, Carrión Alonso G, Olveira Martín A, Segura Cabral JM, González Barón M: Radiofrequency ablation for hepatocellular carcinoma and liver metastases: experience in Hospital La Paz. Clin Transl Oncol; 2006 Sep;8(9):688-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for hepatocellular carcinoma and liver metastases: experience in Hospital La Paz.
  • INTRODUCTION: Radiofrequency ablation for patients presenting with non-resectable primary or metastatic liver tumours seems to be a valid therapeutic alternative.
  • MATERIALS AND METHODS: Twenty two patients were included in this study; eleven of them (50%) sustained liver metastases from colorectal adenocarcinoma, ten patients (45.5%) had hepatocellular carcinoma and 1 patient had insulinoma.
  • RESULTS: Local recurrence rate of hepatocellular carcinoma was 22.7% and 27.3% for colorectal carcinoma, after a respective median follow-up of 21 and 14 months.
  • CONCLUSIONS: Radiofrequency ablation is an easy to make, safe and useful technique for the treatment of primary and metastatic liver tumours.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Spain. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Sep;232(3):381-91 [10973388.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1059-62 [12168073.001]
  • [Cites] Radiology. 1995 Oct;197(1):101-8 [7568806.001]
  • [Cites] Radiology. 2000 Mar;214(3):761-8 [10715043.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Radiology. 1994 Jan;190(1):53-7 [8259428.001]
  • [Cites] J Hepatol. 2000 Oct;33(4):667-72 [11059876.001]
  • [Cites] Hepatology. 2001 Sep;34(3):609-10; author reply 610-1 [11526554.001]
  • [Cites] Eur Radiol. 2001;11(6):914-21 [11419162.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jan;176(1):3-16 [11133529.001]
  • [Cites] Hepatology. 1992 Aug;16(2):353-7 [1322349.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Hepatology. 2001 May;33(5):1124-9 [11343240.001]
  • [Cites] AJR Am J Roentgenol. 1996 Sep;167(3):759-68 [8751696.001]
  • [Cites] Hepatology. 1998 Jan;27(1):67-72 [9425919.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2452-63 [10861420.001]
  • [Cites] Radiology. 2000 Oct;217(1):119-26 [11012432.001]
  • [Cites] AJR Am J Roentgenol. 1998 Apr;170(4):1015-22 [9530052.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):52-8 [12513961.001]
  • [Cites] Dig Dis. 2001;19(4):301-10 [11935090.001]
  • [Cites] Am J Surg. 1999 Dec;178(6):592-9 [10670879.001]
  • [Cites] Radiology. 1999 Mar;210(3):655-61 [10207464.001]
  • [Cites] Gastroenterol Hepatol. 2001 Jun-Jul;24(6):303-11 [11459568.001]
  • [Cites] Hepatology. 1997 Feb;25(2):259-62 [9021931.001]
  • [Cites] AJR Am J Roentgenol. 2003 Aug;181(2):479-84 [12876030.001]
  • (PMID = 17005472.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


87. Lin GH, Wang J, Li SH, Wang J, Xu L, Li SP: Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. Chin J Cancer; 2010 Apr;29(4):403-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma.
  • BACKGROUND AND OBJECTIVE: There are few studies about origins of regulatory T (Treg) cells increased in primary hepatocellular carcinoma (HCC) tissue.
  • Studies showed that Treg cells could be induced by transforming growth factor-beta1 (TGF-beta1), but the relation between TGF-beta1 expression and Treg cell infiltration is unclear in HCC tissue.
  • METHODS: Envision immunohistochemistry was used to detect the expression of TGF-beta1 and Foxp3 in 102 specimens of HCC tissue and paired adjacent non-tumor liver tissue.
  • Average Foxp3+ cell density in HCC was 2.98 cells/HP, but there was very few or no expression of Foxp3 in adjacent non-tumor liver tissue.
  • TGF-beta1 and Foxp3 expression had no correlations with tumor diameter, tumor capsule, liver cirrhosis, and so on.
  • The 5-year survival rate was not different between HCC tissues with high and low TGF-beta1 expression (P = 0.790); however, it was significantly lower in HCC tissues with high Treg cell infiltration than in those low infiltration (25% vs. 44%, P = 0.007).
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms. T-Lymphocytes, Regulatory / pathology. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Forkhead Transcription Factors / metabolism. Humans. Lymphocyte Count. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Survival Rate. Young Adult. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346216.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / alpha-Fetoproteins
  •  go-up   go-down


88. Buyukkurt S, Altintas A, Gumurdulu D, Zeren H, Guzel B: Mucoepidermoid carcinoma of the parotid gland with ovarian and peritoneal metastasis. J Obstet Gynaecol Res; 2008 Apr;34(2):271-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the parotid gland with ovarian and peritoneal metastasis.
  • Metastatic ovarian carcinoma generally arises from the gastrointestinal tract.
  • Mucoepidermoid carcinoma is the most common malignant tumor of the salivary gland.
  • Distant metastasis of the parotid mucoepidermoid carcinoma is very rare, and it usually occurs to the lungs, bones and liver.
  • A 28-year-old woman with a history of high grade mucoepidermoid carcinoma of the parotid gland was admitted with ascites and bilateral ovarian masses.
  • Breast examination, endoscopic evaluation of the gastrointestinal tract, total bone scintigraphy, abdominopelvic and chest tomography and cytological analysis of the ascites did not detect a primary malignancy.
  • Nevertheless, pathological examination of the ovaries revealed a metastasis from the mucoepidermoid carcinoma.
  • [MeSH-major] Carcinoma, Mucoepidermoid / secondary. Ovarian Neoplasms / secondary. Parotid Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412796.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Bensouda Y, André F, Boulet T, Al-Ghuzlan A, Conforti R, Troalen F, Bourgier C, Errihani H, Spielmann M, Delaloge S: [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status]. Bull Cancer; 2009 Oct;96(10):923-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CA 15-3 was elevated in 69% of the cases of HR+ Her2- primary tumors at time of metastatic relapse.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Breast Neoplasms, Male / blood. Breast Neoplasms, Male / pathology. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / blood. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / secondary. DNA-Binding Proteins. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Nuclear Receptor Subfamily 4, Group A, Member 1. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Receptors, Steroid. Retrospective Studies. Skin Neoplasms / secondary. Tumor Burden


90. Stelow EB, Debol SM, Stanley MW, Mallery S, Lai R, Bardales RH: Sampling of the adrenal glands by endoscopic ultrasound-guided fine-needle aspiration. Diagn Cytopathol; 2005 Jul;33(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has proven to be a valuable modality for the primary diagnosis and staging of gastrointestinal, and perigastrointestinal malignancy.
  • Aside from assessing thoracic and abdominal lymph nodes and the liver for metastases, EUS can assess and sample the adrenal glands, which are frequently involved by metastatic disease, but can also harbor benign primary neoplasms.
  • The utility of cell block immunohistochemistry (IHC) in these cases was reviewed.
  • Material for cell block was present in 21 cases, and IHC was used in 3 cases.
  • Final diagnoses were as follows: cortical tissue consistent with cortical adenoma (19), metastatic adenocarcinoma (3), pheochromocytoma (1), and adrenal cortical carcinoma (1).
  • Diagnostic tissue is easily obtained, including material for cell block IHC, which allows definitive diagnosis in cases that present difficult differential diagnoses.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adrenocortical Carcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pheochromocytoma / diagnosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc
  • (PMID = 15945088.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Yates TJ, Abouljoud M, Lambing A, Kuriakose P: Risk of venous thrombosis in patients with hepatic malignancies undergoing surgical resection. Indian J Gastroenterol; 2008 Jul-Aug;27(4):159-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was undertaken to determine whether there was a difference in the risk of thrombosis between those undergoing resection for hepatic metastases and primary hepatic malignancies.
  • We performed a retrospective chart review of patients undergoing initial surgical resection for hepatic malignancies, primarily to determine whether there was a difference in the incidence of venous thrombosis between those with primary and secondary malignancies.
  • Ninety-nine patients underwent surgical resection for either primary or secondary hepatic malignancies from 2001 to 2006.
  • This retrospective review reveals that a clinical presentation of venous thrombosis is significantly more common among patients undergoing hepatic resection for secondary malignancy than those undergoing resection for primary cancer of the liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / adverse effects. Liver Neoplasms / surgery. Venous Thrombosis / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Confounding Factors (Epidemiology). Female. Humans. Incidence. Male. Medical Records. Middle Aged. Neoplasm Metastasis / therapy. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Risk

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18974467.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


92. Nakamura T, Fuwa N, Kodaira T, Tachibana H, Tomoda T, Nakahara R, Inokuchi H: Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung; 2008 Mar-Apr;186(2):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy.
  • Primarily combined radiotherapy and chemotherapy are used to treat unresectable non-small-cell lung cancer; however, the results are not satisfactory.
  • From March 1999 to January 2004, 102 patients with stage IIIA/IIIB non-small-cell lung cancer received definitive radiotherapy with or without chemotherapy.
  • Maximal chemotherapy was given to patients with normal kidney, liver, and bone marrow functions.
  • Patients whose primary tumor is located in the superior lobe appear to have a better clinical outcome.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prognosis. Radiation Pneumonitis / prevention & control. Retrospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1144-51 [15718310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2692-9 [10561343.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3454-60 [12177106.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 2003 Nov;63(9):533-8 [14699861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9 [10487552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):110-5 [12504042.001]
  • [Cites] Chest. 2000 Feb;117(2):358-64 [10669675.001]
  • [Cites] Cancer. 1982 Sep 15;50(6):1091-9 [6286087.001]
  • [Cites] Ann Intern Med. 1996 Nov 1;125(9):723-9 [8929005.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • (PMID = 18097718.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; RSA8KO39WH / Vindesine
  •  go-up   go-down


93. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis


94. Lazaro J, Rubio D, Repolles M, Capote L: Hepatoid carcinoma of the ovary and management. Acta Obstet Gynecol Scand; 2007;86(4):498-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid carcinoma of the ovary and management.
  • The designation'hepatoid carcinoma' has been introduced as a unique type of carcinoma that arises outside the liver but resembles, to a considerable extent, hepatocellular carcinoma both histologically and immunohistochemically in its staining for alpha-fetoprotein (AFP).
  • We, in this study, present a rare patient with primary hepatoid carcinoma of the ovary (OHC) and review the previous reports.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hysterectomy. Liver Neoplasms / pathology. Ovarian Neoplasms / pathology. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Neoplasms, Multiple Primary. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486476.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


95. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS: Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer; 2005 Dec 15;104(12):2753-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
  • BACKGROUND: Biliary tract carcinoma is an aggressive cancer, with median survival rarely exceeding 6 months.
  • A Phase II trial was conducted to study a combination of oral capecitabine and gemcitabine (CapGem) as first-line therapy in patients with advanced and/or metastatic biliary carcinoma.
  • METHODS: Patients with unresectable or metastatic intrahepatic or extrahepatic biliary duct carcinoma and gallbladder carcinoma were enrolled.
  • Primary tumor sites were: intrahepatic (n = 14) and extrahepatic biliary duct (n = 16); gallbladder (n = 7); and ampulla (n = 7).
  • CONCLUSIONS: CapGem is an active and well tolerated first-line combination chemotherapy regimen for patients with advanced/metastatic biliary tract carcinoma that offers a convenient home-based therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / secondary
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bone Neoplasms / secondary. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16294346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, Wang HY: Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int; 2005 Oct;25(5):962-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
  • BACKGROUND/AIM: Expression alteration of Glypican-3 (GPC3) is associated with several malignancies and has been identified as an overexpressed gene in hepatocellular carcinoma (HCC).
  • The average expression level of GPC3 was significantly higher in HCC than that in adjacent liver tissues (P<0.0001).
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Membrane Proteins / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Bile Ducts, Intrahepatic. Diagnosis, Differential. Female. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glypicans. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162153.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPC3 protein, human; 0 / Glypicans; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


97. Gheorghe C, Stanescu C, Gheorghe L, Bancila I, Herlea V, Becheanu G, Voinea D, Iacob R, Lupescu I, Anghel R, Croitoru A, Popescu I: Preoperative noninvasive EUS evaluation in patients with esophageal cancer considered for esophagectomy. J Gastrointestin Liver Dis; 2006 Jun;15(2):137-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of the 220 patients, 41 patients, with no major comorbidities contraindicating esophagectomy already having been screened by abdominal and thoracic CT to disclose distant metastases, had EUS with the definite purpose of staging esophageal carcinoma and selecting adequate therapy.
  • Preoperative EUS staging changed the decision for surgery in 18 of 41 patients (44%) (p<0.0001) and allowed primary esophagectomy in only 6 patients (15%) (p<0.0001).
  • [MeSH-major] Adenocarcinoma / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Esophageal Neoplasms / ultrasonography. Esophagectomy. Patient Selection
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Preoperative Care. Prospective Studies

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16802008.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


98. Ye XP, Li LQ, Peng T, Xiao KY, Su ZX, Shang LM, Su M, Xu BH: [Diagnosis and treatment of primary clear cell carcinoma of the liver]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary clear cell carcinoma of the liver].
  • OBJECTIVE: To investigate the clinicopathological features, diagnosis, treatment and prognosis of primary clear cell carcinoma of the liver (PCCCL).
  • Liver cirrhosis was found in 75.0% of the patients.
  • CONCLUSION: The clinical characteristics of primary clear cell carcinoma of the liver are similar to that of common hepatocellular carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatitis B. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211073.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


99. Brueckl WM, Schoeberl A, Wirtz RM, Murray S, Hahn EG, Wiest GH: Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol; 2008 Mar;3(3):314-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
  • A 37-year-old female never smoker with metastatic large cell carcinoma of the lung had a partial response to a second line palliative therapy with the EGF-R tyrosine kinase inhibitor erlotinib after platinum based first line therapy failed.
  • Molecular analysis of the primary and a liver metastasis did neither find any EGF-R mutation nor an EGF-R amplification.
  • However, both the primary and the metastasis showed an increased gene expression of vascular-endothelial growth factor-A in contrast to normal tissue, which was confirmed by immunohistochemistry.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / metabolism. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adult. Erlotinib Hydrochloride. Fatal Outcome. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Mutation. Protein Kinase Inhibitors / therapeutic use. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317076.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


100. Kassahun WT, Fangmann J, Harms J, Hauss J, Bartels M: Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Transplant; 2006 Dec;4(2):549-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection and transplantation in the management of hepatocellular carcinoma: a review.
  • Hepatocellular carcinoma (HCC) accounts for more than 80% of all primary liver cancers and is one of the most common malignancies worldwide.
  • Effective treatment for HCC includes liver resection and liver transplantation.
  • Partial hepatectomy is the therapy of choice in patients with HCC and a noncirrhotic liver.
  • Usually, liver transplantation is not indicated for such patients, although in individual cases, transplantation may be considered.
  • For most cirrhotic patients who fulfill the Milan criteria, liver transplantation is the ultimate treatment option.
  • Liver transplantation restores liver function and ensures the removal of all hepatic foci of tumor as well as tissue with a high oncogenic potential for early tumor recurrence.
  • Because of the present lack of available organs, living-donor liver transplantation (LDLT) is an increasingly popular alternative.
  • Strategies to reduce tumor growth in patients who are awaiting liver transplantation are important to ensure that those individuals continue to fulfill the Milan criteria for transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Liver Transplantation / physiology. Tissue Donors. Tissue and Organ Harvesting / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238857.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 99
  •  go-up   go-down






Advertisement